[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 752
1. Lim ST, Levine AM: Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin; 2005 Jul-Aug;55(4):229-41; 260-1, 264
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.
  • Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.
  • With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.
  • Over the last few years, advances in our understanding of the molecular biology of this heterogeneous group of lymphomas have led to the adoption of new classification systems.
  • Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.
  • Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020424.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


2. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA: Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol; 2010 Feb 10;28(5):773-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating serum free light chains as predictive markers of AIDS-related lymphoma.
  • PURPOSE HIV-infected persons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increased in the era of effective HIV therapy.
  • We evaluated serum immunoglobulin (Ig) proteins as predictors of NHL risk among HIV-infected individuals.
  • PATIENTS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 individuals who developed NHL and 225 matched (by cohort, sex, ethnicity, age, and CD4 count), HIV-infected, lymphoma-free controls who had available stored prediagnostic blood samples.
  • M proteins were detected in only two patients with NHL (3%) and in nine controls (4%), and they were not significantly associated with NHL risk.
  • CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood. Lymphoma, AIDS-Related / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]
  • [Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]
  • [Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Curr HIV Res. 2004 Jan;2(1):11-21 [15053337.001]
  • [Cites] AIDS Read. 2004 Jul;14(7):372-4, 377-9 [15282866.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1548-63 [15470219.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):453-8 [6224088.001]
  • [Cites] JAMA. 1987 Jan 16;257(3):331-4 [3491911.001]
  • [Cites] Clin Chem. 1987 Sep;33(9):1697-8 [3621592.001]
  • [Cites] Clin Chem. 1989 Feb;35(2):338-9 [2914402.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] Br J Haematol. 1993 May;84(1):151-5 [8101720.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2150-6 [9447834.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):296-300 [15688390.001]
  • [Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]
  • [Cites] Haemophilia. 2005 Sep;11(5):516-28 [16128897.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]
  • [Cites] Clin Infect Dis. 2006 Nov 1;43(9):1198-205 [17029142.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] N Engl J Med. 2009 Apr 30;360(18):1815-26 [19339714.001]
  • (PMID = 20048176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA 62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  • [Other-IDs] NLM/ PMC2834393
  •  go-up   go-down


3. Lamers SL, Fogel GB, Huysentruyt LC, McGrath MS: HIV-1 nef protein visits B-cells via macrophage nanotubes: a mechanism for AIDS-related lymphoma pathogenesis? Curr HIV Res; 2010 Dec;8(8):638-40
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 nef protein visits B-cells via macrophage nanotubes: a mechanism for AIDS-related lymphoma pathogenesis?
  • This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1).
  • The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes.
  • Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered.
  • ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation.
  • In this letter we discuss several studies that link HIV-infected macrophages and specific forms of the nef protein to the development of ARL.
  • The conduits discovered by Xu et al. may lead to a better understanding of how HIV infection results in lymphomagenesis.
  • [MeSH-major] B-Lymphocytes / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / physiopathology. Macrophages / immunology. nef Gene Products, Human Immunodeficiency Virus / metabolism
  • [MeSH-minor] HIV Infections / immunology. HIV Infections / virology. HIV-1 / physiology. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Host Microbe. 2008 Jul 17;4(1):63-76 [18621011.001]
  • [Cites] IEEE/ACM Trans Comput Biol Bioinform. 2008 Apr-Jun;5(2):291-300 [18451438.001]
  • [Cites] Nat Immunol. 2009 Sep;10(9):933-4 [19692990.001]
  • [Cites] Nat Immunol. 2009 Sep;10(9):1008-17 [19648924.001]
  • [Cites] Hum Immunol. 2009 May;70(5):325-30 [19236898.001]
  • [Cites] Nucleic Acids Res. 2009 Oct;37(19):6575-86 [19729508.001]
  • [Cites] PLoS One. 2009;4(12):e8153 [19997510.001]
  • [Cites] Immunol Cell Biol. 2010 Jan;88(1):1-2 [19859083.001]
  • [Cites] J Leukoc Biol. 2010 Apr;87(4):599-608 [20042468.001]
  • [Cites] J Leukoc Biol. 2010 Apr;87(4):627-32 [20042471.001]
  • [Cites] Retrovirology. 2010;7:33 [20380696.001]
  • [Cites] J Immunol. 2009 Aug 15;183(4):2415-24 [19620308.001]
  • [Cites] J Virol. 2001 Apr;75(8):3657-65 [11264355.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):97-107 [12563294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5011-5 [1711215.001]
  • [Cites] Virology. 1993 Nov;197(1):420-5 [8212577.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Aug;10(8):1003-10 [7811531.001]
  • [Cites] Cell. 1996 Jun 14;85(6):931-42 [8681387.001]
  • [Cites] Res Virol. 1997 Jan-Feb;148(1):68-70 [9017838.001]
  • [Cites] Clin Rev Allergy Immunol. 1996-1997 Winter;14(4):359-66 [9040966.001]
  • [Cites] Eur J Biochem. 1997 Aug 1;247(3):843-51 [9288906.001]
  • [Cites] Nat Med. 1999 Sep;5(9):997-103 [10470075.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51688-96 [15459189.001]
  • [Cites] J Gen Virol. 2006 Mar;87(Pt 3):563-71 [16476977.001]
  • [Cites] Exp Cell Res. 2006 Nov 1;312(18):3659-68 [16978607.001]
  • [Cites] Virology. 2006 Nov 25;355(2):175-91 [16916529.001]
  • [Cites] J Leukoc Biol. 2008 May;83(5):1136-44 [18285406.001]
  • [Cites] Semin Cancer Biol. 2008 Oct;18(5):349-55 [18467122.001]
  • (PMID = 21067513.001).
  • [ISSN] 1873-4251
  • [Journal-full-title] Current HIV research
  • [ISO-abbreviation] Curr. HIV Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066529; United States / NCI NIH HHS / CA / U01 CA066529; United States / NIMH NIH HHS / MH / U19 MH081835; United States / NIMH NIH HHS / MH / U19 MH081835
  • [Publication-type] Letter; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / nef Gene Products, Human Immunodeficiency Virus; 0 / nef protein, Human immunodeficiency virus 1
  • [Other-IDs] NLM/ NIHMS407811; NLM/ PMC3471533
  •  go-up   go-down


Advertisement
4. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA: RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med; 2010 Jun 16;2(36):36ra43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
  • AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells.
  • As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).
  • In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.
  • Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-related toxicities.
  • These results support the development of an RNA-based cell therapy platform for HIV.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1182-8 [17406343.001]
  • [Cites] Hum Gene Ther. 2008 Jun;19(6):622-34 [18533892.001]
  • [Cites] J Gene Med. 2008 Oct;10(10):1059-70 [18642399.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]
  • [Cites] Mol Ther. 2009 May;17(5):844-50 [19259065.001]
  • [Cites] Science. 2009 Nov 6;326(5954):818-23 [19892975.001]
  • [Cites] Gene Ther. 2010 Mar;17(3):389-99 [19865182.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Mol Ther. 2002 Apr;5(4):479-84 [11945076.001]
  • [Cites] Gene Ther. 2002 Aug;9(16):1055-64 [12140733.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1730-4 [12457288.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):325-33 [12668128.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):62-71 [12842429.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] Blood. 2004 Feb 1;103(3):796-803 [12920024.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] J Gene Med. 2004 Mar;6(3):268-77 [15026988.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):395-6 [3166513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 [1409715.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4618-28 [8639830.001]
  • [Cites] Gene Ther. 1996 Aug;3(8):717-24 [8854097.001]
  • [Cites] J Virol. 1997 Jun;71(6):4707-16 [9151864.001]
  • [Cites] J Virol. 1999 May;73(5):3649-60 [10196257.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Clin Immunol. 2005 Apr;115(1):26-32 [15870017.001]
  • [Cites] Mol Ther. 2005 Jul;12(1):77-86 [15963923.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):697-706 [16039909.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):900-9 [16115802.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):366-73 [16325473.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1751-60 [16269617.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):1003-10 [16511767.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3305-12 [16857988.001]
  • [Cites] Mol Ther. 2007 May;15(5):1024-33 [17356541.001]
  • [Cites] Methods Mol Biol. 2008;434:99-112 [18470641.001]
  • (PMID = 20555022.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS305014; NLM/ PMC3130552
  •  go-up   go-down


5. Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H: Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect; 2006 Apr;8(5):1301-7
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.
  • A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.
  • The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).
  • Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).
  • Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.
  • Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).
  • Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.
  • Kaposi's sarcoma-associated herpesvirus infection was rare (4%) among all cases.
  • These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697236.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


6. Kawabata KC, Hagiwara S, Takenouchi A, Tanimura A, Tanuma J, Tachikawa N, Miwa A, Oka S: Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases. Intern Med; 2009;48(2):111-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.
  • AIDS-related lymphoma (ARL) is a serious complication of HIV infection.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antiretroviral Therapy, Highly Active. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. HIV Infections / drug therapy. Humans. Male. Melphalan / administration & dosage. Nitrosourea Compounds / administration & dosage. Recurrence. Salvage Therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145056.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; RYH2T97J77 / ranimustine
  •  go-up   go-down


7. Combs S, Neil N, Aboulafia DM: Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study. Oncologist; 2006 Jun;11(6):666-73
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study.
  • PURPOSE: To evaluate in a pilot study the safety and efficacy of liposomal doxorubicin, cyclophosphamide, and etoposide (LACE) when combined with antiretroviral therapy (ART) in patients with AIDS-related lymphoma (ARL).
  • The impact of HIV viral control on therapy and survival was also assessed.
  • RESULTS: The median patient CD4+ count was 190 cells/microl (range, 20-510 cells/microl), and the median HIV viral load (VL) was 61,613 copies/ml (range, <50-500,000 copies/ml).
  • Six patients (50%) were ART-naïve, five were viremic despite ART, and one had an undetectable HIV-1 VL.
  • HIV viral control can be maintained in the majority of patients during and after completion of LACE.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794245.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Drug Carriers; 0 / Liposomes; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1
  •  go-up   go-down


8. Epeldegui M, Vendrame E, Martínez-Maza O: HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res; 2010 Dec;48(1-3):72-83
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.
  • HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).
  • The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.
  • In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.
  • [MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]
  • [Cites] J Virol. 2001 Jul;75(13):6173-82 [11390619.001]
  • [Cites] AIDS. 2001 May 25;15(8):957-64 [11399977.001]
  • [Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]
  • [Cites] Eur J Immunol. 2001 May;31(5):1544-9 [11465112.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):609-20 [12974476.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5215-24 [14607922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(11):3456-60 [6222380.001]
  • [Cites] Science. 1986 Sep 5;233(4768):1084-6 [3016902.001]
  • [Cites] J Immunol. 1987 Jun 1;138(11):3720-4 [2953790.001]
  • [Cites] Immunol Today. 1989 May;10(5):153-7 [2525911.001]
  • [Cites] J Exp Med. 1989 Dec 1;170(6):2081-95 [2531194.001]
  • [Cites] Immunology. 1989 Dec;68(4):526-31 [2481643.001]
  • [Cites] AIDS. 1992 Oct;6(10):1105-16 [1466841.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3430-6 [8241510.001]
  • [Cites] Eur J Immunol. 1994 Aug;24(8):1869-73 [8056045.001]
  • [Cites] Immunol Today. 1994 Sep;15(9):418-22 [7524519.001]
  • [Cites] J Immunol. 1995 Mar 15;154(6):2533-44 [7533177.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1843-9 [7703491.001]
  • [Cites] Mol Med. 1995 Jul;1(5):495-505 [8529116.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Leuk Lymphoma. 1998 Jul;30(3-4):257-67 [9713958.001]
  • [Cites] Clin Immunol. 1999 Feb;90(2):157-64 [10080826.001]
  • [Cites] Blood. 1999 Jul 1;94(1):275-82 [10381523.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Clin Immunol. 1999 Nov;93(2):114-23 [10527687.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7912-9 [15944297.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]
  • [Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18093-8 [16330748.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3931-41 [16547227.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Mol Immunol. 2007 Jan;44(4):494-505 [16574227.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3859-64 [16882707.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]
  • [Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2545-52 [17132718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]
  • [Cites] Transl Res. 2007 Apr;149(4):231-5 [17383597.001]
  • [Cites] J Virol. 2007 Jun;81(11):5872-81 [17392362.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):3153-60 [17709530.001]
  • [Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):186-9 [18566383.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]
  • [Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1745-55 [19165855.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):967-73 [19114696.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):5968-73 [19773382.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Dec 11;390(2):269-72 [19799865.001]
  • [Cites] Mol Immunol. 2009 Nov;47(1):3-7 [19193443.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):631-41 [19941823.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):351-65 [19619654.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):401-6 [19619656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22421-6 [20080792.001]
  • [Cites] Int J Cancer. 2010 Mar 15;126(6):1316-26 [19530237.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Cytokine. 2010 Apr;50(1):58-68 [20060740.001]
  • [Cites] J Leukoc Biol. 2010 Apr;87(4):627-32 [20042471.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):18-26 [20216076.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jul;59(7):979-87 [20352428.001]
  • [Cites] Br J Haematol. 2010 May;149(4):484-97 [20346013.001]
  • [Cites] Biochem Biophys Res Commun. 2010 May 21;396(1):67-73 [20494113.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Inflamm Bowel Dis. 1999 Nov;5(4):285-94 [10579123.001]
  • [Cites] Clin Immunol. 1999 Dec;93(3):239-44 [10600334.001]
  • [Cites] J Allergy Clin Immunol. 2000 May;105(5):975-82 [10808179.001]
  • [Cites] AIDS. 2000 Jul 7;14(10):1460-1 [10930167.001]
  • (PMID = 20717742.001).
  • [ISSN] 1559-0755
  • [Journal-full-title] Immunologic research
  • [ISO-abbreviation] Immunol. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA073475
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS461037; NLM/ PMC3640300
  •  go-up   go-down


9. Barclay LR, Buskin SE, Kahle EM, Aboulafia DM: Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma Myeloma; 2007 Jan;7(4):272-9
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Despite the decrease in HIV-associated morbidity and mortality with the advent of highly active antiretroviral therapy (HAART), the incidence of AIDS-related lymphoma (ARL) has not decreased as significantly.
  • We used the Adult and Adolescent Spectrum of HIV-Related Diseases database of Public Health-Seattle and King County to determine incidences and trends among patients with ARL in Seattle/King County, WA.
  • There was also a significant increase in patients diagnosed with ARL at CD4+ counts > or = 200 cells/microL (3% vs. 21%) and a large decrease in median HIV-1 viral loads at ARL diagnosis (264,667 copies/mL vs. 35,500 copies/mL).
  • This changing profile of patients with ARL parallels larger changes seen among the general AIDS population in the HAART era.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324334.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 30
  •  go-up   go-down


10. Sabin CA: HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy. J Infect Dis; 2009 Jul 1;200(1):8-10
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. HIV Infections / drug therapy. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Anti-HIV Agents / adverse effects. Anti-HIV Agents / therapeutic use. Humans


11. Lu P, Yang C, Guasparri I, Harrington W, Wang YL, Cesarman E: Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. Leukemia; 2009 Apr;23(4):807-10
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Receptors, Antigen, B-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987659.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


12. Miralles Alonso F, Ortega González LM, Oropesa González L, Francisco RD, de Paz VC: [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005]. Rev Cubana Med Trop; 2006 Sep-Dec;58(3):248-53
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005].
  • [Transliterated title] Comportamiento de linfoma relacionado con VIH/SIDA en el Instituto "Pedro Kourí". 2004-2005.
  • A prospective and descriptive study of 20 patients infected with HIV and admitted to "Pedro Kouri" Institute of Tropical Disease after a diagnosis of lymphoma was conducted.
  • They were all evaluated at the onset of diagnosis by a thorough medical record exam and supportive studies such as complete blood count, globular sedimentation speed, CD4+ count, lactic acid dehydrogenase, HIV viral load, cytology and biopsy.
  • It called our attention that high levels of lactic acid dehydrogenase and extrapulmonary location of tumors were related.
  • Statistically significant association was found (p < 0.05) between immunosuppresion condition of the patients given by CD4+ count below 350 cell/mm3 and advanced staging of the tumoral disease (stages III and IV).
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23424794.001).
  • [ISSN] 0375-0760
  • [Journal-full-title] Revista cubana de medicina tropical
  • [ISO-abbreviation] Rev Cubana Med Trop
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Cuba
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


13. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, Hamouda O, ClinSurv Study Group: Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis; 2009 Jul 1;200(1):79-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
  • BACKGROUND: AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART).
  • We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma.
  • METHODS: Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model.
  • RESULTS: In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P < .001]).
  • This association differed markedly between lymphoma subtypes.
  • Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997).
  • Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment.
  • CONCLUSIONS: Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART.
  • The influence of cumulative HIV viremia may differ between lymphoma subtypes.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Viremia / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2009 Jul 1;200(1):8-10 [19476436.001]
  • (PMID = 19476437.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Kuehne A; Arastéh K; Kowol S; Bergmann F; Warnke M; Brockmeyer N; Mühlbächer N; Rockstroh J; Wasmuth J; Oette M; Blondin C; Esser S; Schenk-Westkamp P; Plettenberg A; Lorenzen T; Walther I; Adam A; Weitner L; Schewe K; Goey H; Fenske S; Buhk T; Gellerman H; Wassmuss K; Stoll M; Gerschmann S; Horst H; Fätkenheuer G; Kümmerle T; Gillor D; Bogner J; Sonntag B; Salzberger B; Fritzsche C
  •  go-up   go-down


14. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib.
  • : e19562 PBL are a group of highly aggressive neoplasms originally described in the oral cavity and jaws of HIV-infected patients.
  • An AIDS-defining illness, PBL comprises 2.6% of AIDS-related lymphomas.
  • A 42-year-old male with newly diagnosed AIDS presented with nausea, vomiting, bloody diarrhea and epigastric pain.
  • The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.
  • Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.
  • We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gercovich FG, Gil Deza E, Martin Reina G, Garcia Gerardi C, Abal M, Santillan D, Tognelli F, Calarame J, Rivarola E, Morgenfeld E: 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real? J Clin Oncol; 2009 May 20;27(15_suppl):e17535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real?
  • : e17535 Background: Juvenile Cancer (JC) involves patients between 18 and 29 years old (adult pt less than 30 yo) and can be or not associated to AIDS.
  • The non-AIDS JC pt challenge the clinical oncologist in many ways: there are few preventive measures, avoiding delayed toxicities is mandatory (fertility, cognitive impairment) and there is a lack of evidence-based treatments for uncommon tumors.
  • The aim of this paper is to evaluate the incidence and clinical outcome of JC non AIDS related at the IOHM.
  • The tumors were classified as expected (germinal, hematological, sarcoma, melanoma, CNS, thyroid, cervix, trophoblastic disease) or unexpected (breast, colon, ovarian, gastric, pancreatic, head and neck).
  • DIAGNOSIS: Expected tumors 269 pt (80%) (testicular tumors = 89 pt; lymphoma = 75 pt; sarcoma = 35 pt; melanoma = 17 pt; others = 53), Unexpected tumors 67 pt (20%) (gastrointestinal = 23 pt; breast cancer = 17 pt; ovarian = 13 pt; head and neck = 7 pt; others = 7 pt).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Castillo J, Milani C, Pantanowitz L: HIV-associated anaplastic large cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated anaplastic large cell lymphoma.
  • : e19563 Background: Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell lymphoma that is generally unrelated to EBV in the non-HIV setting.
  • Based upon anaplastic lymphoma kinase (ALK) expression, the new WHO classification provisionally distinguishes between ALK+ (favorable) and ALK- (unfavorable) ALCL.
  • The characteristics of ALCL, such as ALK expression and EBV coinfection, in individuals with HIV infection have not been adequately evaluated.
  • The aim of this study was to investigate these features in HIV-associated ALCL cases.
  • METHODS: A MEDLINE search for all cases of HIV-associated non-cutaneous ALCL was undertaken.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, ALK expression, molecular studies), EBV coinfection, therapy and outcome (survival, cause of death) were extracted and analyzed.
  • Median CD4+ count was 76 cells/mm3 and HIV viral load 416,500 copies/ml.
  • Many (78%) patients had stage IV disease and B symptoms were reported in 9 cases (50%).
  • Death was caused by either lymphoma progression (42%) or infection (58%).
  • CONCLUSIONS: HIV-associated non-cutaneous ALCL appears to affect younger individuals and is associated with EBV infection in a subset of cases.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated ALCL appears to be related to the absence of ALK expression, advanced stage at presentation with prominent extranodal disease, inadequate therapy including HAART, and poor response to CHOP.
  • Further research is needed to better understand and treat this unique HIV-associated lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961064.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Reategui RD, Beltran B, Morales D, Vera L, Quinones P, Portugal K, Desposorio C, Capellino A, Castillo J: AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.
  • METHODS: The clinical records of 2,502 HIV-infected patients seen in our institution from March 1997 to March 2008 were reviewed.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.
  • In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cheung MC, Imrie KR, Leitch HA, Park-Wyllie LY, Buckstein R, Antoniou T, Loutfy MR: Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma. Ann Hematol; 2007 Sep;86(9):631-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma.
  • The optimal management of acquired immunodeficiency syndrome-related lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is unclear.
  • Of 196 lymphoma-treating physicians, 117 (63%) responded.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Physicians / psychology. Practice Patterns, Physicians' / statistics & numerical data
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / utilization. Canada. Choice Behavior. Cyclophosphamide / therapeutic use. Data Collection. Disease Management. Doxorubicin / therapeutic use. Humans. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372734.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Kim JS, Kim SJ, Kim JS, Kim ES, Shin HJ, Chung JS, Min YH, Lee MH, Choi YJ, Bang SM, Kim JA, Cho GJ, Chi HS, Jang SS, Park CJ, Suh C, Park CW, Kim CS, Korean Society of Hematology Lymphoma Working Party: Report of AIDS-related lymphoma in South Korea. Jpn J Clin Oncol; 2008 Feb;38(2):134-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of AIDS-related lymphoma in South Korea.
  • BACKGROUND: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea.
  • RESULTS: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS.
  • The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included.
  • Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes.
  • The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded.
  • As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Korea / epidemiology. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / therapy. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18263652.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


20. Levine AM: AIDS-related lymphoma. Semin Oncol Nurs; 2006 May;22(2):80-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoma.
  • OBJECTIVE: To review the epidemiology, pathology, clinical features, prognostic factors, and treatment approaches of patients with AIDS-related lymphoma.
  • CONCLUSION: Aggressive B-cell lymphoma has become one of the more common of the initial AIDS-defining illnesses in the United States.
  • Median survival of affected patients has improved considerably with the use of highly active anti-retroviral therapy directed against human immunodeficiency virus, along with multi-agent chemotherapy, and outcome of such patients now approaches that of human immunodeficiency virus-negative patients with aggressive lymphoma.
  • IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses must be knowledgeable of AIDS-related lymphoma to provide supportive care to this patient population.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720230.001).
  • [ISSN] 0749-2081
  • [Journal-full-title] Seminars in oncology nursing
  • [ISO-abbreviation] Semin Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


21. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood; 2009 Aug 13;114(7):1306-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
  • After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in HIV-positive patients with Hodgkin (HL) and non-Hodgkin (NHL) lymphoma.
  • Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50 HIV-positive HAART-responding patients with refractory/relapsed lymphoma.
  • After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant disease, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.
  • Twenty-one patients are alive and disease-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).
  • Only lymphoma response significantly affected OS after transplantation.
  • In multivariate analyses both lymphoma stage and low CD4 count negatively influenced the possibility to receive transplant.
  • PBSCT is a highly effective salvage treatment for chemosensitive AIDS-related lymphoma.
  • It seems rational to explore its use earlier during the course of lymphoma to increase the proportion of patients who can actually receive transplant.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous


22. Tulpule A: Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol; 2005 Sep;17(5):466-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance in AIDS-related lymphoma.
  • PURPOSE OF REVIEW: AIDS-related lymphoma has a decreased response rate and poorer prognosis to standard chemotherapy when compared with lymphoma in the non-HIV population.
  • In addition to the known HIV-related and lymphoma-related poor prognostic factors, this review discusses another factor, MDR-1 expression and its impact on response to therapy in patients with AIDS-related lymphoma.
  • RECENT FINDINGS: There is an increased incidence of de-novo MDR-1 expression in AIDS-related lymphoma compared with lymphoma in the non-HIV settings.
  • MDR-1 expression in AIDS-related lymphoma is associated with poor response to conventional combination chemotherapy.
  • Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma.
  • SUMMARY: The overexpression of MDR-1 gene product P-glycoprotein is an adverse prognostic factor in AIDS-related lymphoma.
  • Treatment with liposomal encapsulated doxorubicin seems to overcome the P-glycoprotein-related drug resistance.
  • This and other strategies to modulate MDR-1 should be further explored in order to improve success rates in the treatment of AIDS-related lymphoma.
  • [MeSH-major] Drug Resistance, Multiple, Viral / genetics. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / genetics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093797.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 23
  •  go-up   go-down


23. Cuéllar Ponce de León LE Sr, Miranda Rosales LM Sr, Biminchumo Zagástegui C, Rosales Cusichaqui R, Flores C Sr, Mas López L Sr, León Chong J Sr: Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e20550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007.
  • : e20550 Background: The introduction of the highly active antiretroviral therapy (HAART) has changed the clinical course of acquired immune deficiency syndrome (AIDS) related to cancer.
  • The goals were to describe the the characteristics of AIDS related to cancer before and after HAART in patients in a Hospital of a resource-limited country.
  • The number of invasive cervical cancer (CC) and AIDS-related lymphomas (ARLs) increased in the Post HAART era; the number on non-HIV/AIDS related to cancer has decreased.
  • CONCLUSIONS: The introduction of HAART has reduced the number of non-VIH/AIDS related cancer, but have increased the CC and LNH and improved the survival of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Baik SJ, Shim KN, Choi HJ, Jung SA, Yoo K: [Small bowel lymphoma detected by MiroCam capsule endoscope in a patient with acquired immune deficiency syndrome]. Korean J Gastroenterol; 2008 Jul;52(1):37-41
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small bowel lymphoma detected by MiroCam capsule endoscope in a patient with acquired immune deficiency syndrome].
  • Human immunodeficiency virus (HIV) infection is a risk factor for developing non-Hodgkin's lymphoma.
  • Most acquired immune deficiency syndrome (AIDS)-related lymphomas are high-grade B cell non-Hodgkin's lymphomas.
  • The use of highly active antiretroviral therapy has reduced the incidence of AIDS-related lymphoma.
  • There have been 7 reports of AIDS-related extra-nodal lymphoma in Korea.
  • We report a case of AIDS-related lymphoma detected by MiroCam capsule endoscopy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Capsule Endoscopes. Jejunal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / virology. Humans. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077490.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


25. Milani C, Castillo J: HIV-associated peripheral T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated peripheral T-cell lymphoma.
  • : e19551 Background: T-cell lymphomas (TCL) constitute 3% of all AIDS-related lymphomas.
  • Over the past 2 decades numerous case reports have documented the emergence of TCL among HIV-infected individuals.
  • These lymphomas comprise a diverse group of disease entities, including peripheral T-cell lymphomas (PTCL), which represent the most common subtype.
  • The aim of this study was to investigate the clinical and pathological features of HIV-associated PTCL.
  • METHODS: A MEDLINE search for cases of HIV-associated PTCL was conducted through December 2008.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), use of HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, molecular studies), EBV coinfection, therapy, and outcome (survival, cause of death) were analyzed and reported descriptively.
  • Stage III and IV disease was found in 17 and 5 cases, respectively, accounting for 76% of the total cases.
  • Twenty-two patients (69%) died complicated by infections in 57% and lymphoma progression in 36% of cases.
  • CONCLUSIONS: HIV-associated PTCL tends to affect young male individuals with low CD4 counts.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated PTCL appears to be related to advanced stage at presentation, presence of B symptoms, elevated LDH levels, prominent extranodal disease, and poor response to CHOP chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Corti M, Villafañe MF, Trione N, Schtirbu R, Narbaitz M: Primary pulmonary AIDS-related lymphoma. Rev Inst Med Trop Sao Paulo; 2005 Jul-Aug;47(4):231-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary AIDS-related lymphoma.
  • Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).
  • However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.
  • Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.
  • We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138208.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


27. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


28. Hoffmann C, Repp R, Schoch R, Gahn B, Schub N, Beck C, Humpe A, Kneba M, Horst HA, Schmitz N, Gramatzki M: Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma. Eur J Med Res; 2006 Feb 21;11(2):73-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma.
  • There is now evidence that the tolerability and response to systemic chemotherapy in HIV-infected patients with AIDS-related lymphoma (ARL) is significantly improved by highly active antiretroviral therapy.
  • Here we report an severely immunocompromised AIDS patient with recurrent ARL who was successfully treated with autologous stem cell transplantation (ASCT).
  • We also review the current literature of ASCT in HIV-infected patients.
  • [MeSH-major] B-Lymphocytes / pathology. Hematopoietic Stem Cell Transplantation. Immunocompromised Host. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. HIV Infections / complications. HIV Infections / pathology. Humans. Male. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504964.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Nagai H, Iwasaki N, Odawara T, Okada S: Actual status of AIDS-related lymphoma management in Japan. Int J Hematol; 2008 May;87(4):442-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actual status of AIDS-related lymphoma management in Japan.
  • [MeSH-major] Lymphoma, AIDS-Related / etiology. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389175.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Burton A: HAART and CHOP improve survival in AIDS-related lymphoma. Lancet Oncol; 2006 Apr;7(4):290
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAART and CHOP improve survival in AIDS-related lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma / drug therapy. Lymphoma / virology


31. Dunleavy K, Wilson WH, Kaplan LD: The case for rituximab in AIDS-related lymphoma. Blood; 2006 Apr 1;107(7):3014-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for rituximab in AIDS-related lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Non-Hodgkin / drug therapy. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • (PMID = 16554492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


32. Kanmogne GD: Noninfectious pulmonary complications of HIV/AIDS. Curr Opin Pulm Med; 2005 May;11(3):208-12
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninfectious pulmonary complications of HIV/AIDS.
  • PURPOSE OF REVIEW: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era.
  • RECENT FINDINGS: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients.
  • This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients.
  • The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients.
  • Concurrent use of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma.
  • For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment.
  • SUMMARY: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies.
  • Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer.
  • The full impact of HAART on HIV pulmonary hypertension remains to be determined.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Hypertension, Pulmonary / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Comorbidity. Female. HIV Infections / diagnosis. HIV Infections / drug therapy. HIV Infections / epidemiology. Humans. Incidence. Male. Prognosis. Severity of Illness Index. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818181.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 1KO1MH068214-1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


33. El-Salem M, Raghunath PN, Marzec M, Liu X, Kasprzycka M, Robertson E, Wasik MA: Activation of mTORC1 signaling pathway in AIDS-related lymphomas. Am J Pathol; 2009 Aug;175(2):817-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of mTORC1 signaling pathway in AIDS-related lymphomas.
  • Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma.
  • These cases represented a diverse spectrum of histological types of non-Hodgkin lymphoma (24 cases) and classic Hodgkin lymphoma (five cases).
  • mTORC1 was also activated in the hyperplastic but not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion that mTORC1 activation is a common feature of transformed lymphocytes irrespective of either their reactive or malignant phenotype.
  • We also found that in B-cell lines that represent diffuse large B-cell lymphoma, Burkitt lymphoma, Epstein-Barr virus-infected lymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and, seemingly, phosphoinositide 3 kinases suppressed mTORC1 activation, in particular when these inhibitors were used in combination.
  • These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or, possibly, upstream activators of the mTORC1 pathway.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4070-80 [12145207.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21960-71 [12668683.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]
  • [Cites] Biochimie. 2003 Aug;85(8):763-9 [14585543.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Pediatr Transplant. 2004 Jun;8(3):243-8 [15176961.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):14846-9 [1869521.001]
  • [Cites] J Biol Chem. 1992 Apr 25;267(12):8613-9 [1569106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9107-11 [1409610.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15900-5 [8340414.001]
  • [Cites] J Biol Chem. 1993 Nov 15;268(32):24442-8 [8226994.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5918-25 [8119935.001]
  • [Cites] J Immunol. 1994 Jun 1;152(11):5429-37 [8189062.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]
  • [Cites] Immunol Lett. 1999 Jun 1;68(2-3):301-9 [10424436.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19937-47 [15760907.001]
  • [Cites] Nephrol Dial Transplant. 2005 Aug;20(8):1748-51 [15919698.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):e67-72 [16632009.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26904-13 [16816403.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6347-60 [17041621.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] Lab Invest. 2007 Jan;87(1):29-39 [17075574.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1267-71 [17524950.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Transplant Proc. 2007 Jul-Aug;39(6):2036-7 [17692685.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2181-9 [18025151.001]
  • [Cites] Transpl Int. 2008 Jun;21(6):605-8 [18282244.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]
  • [Cites] Transplantation. 2003 May 27;75(10):1710-7 [12777861.001]
  • (PMID = 19608873.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089194; United States / NIDCR NIH HHS / DE / R01 DE017337; United States / NCI NIH HHS / CA / R01-CA89194; United States / NIDCR NIH HHS / DE / R01-DE-017337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Phospho-Specific; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 17885-08-4 / Phosphoserine; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2716976
  •  go-up   go-down


34. Vera L, Reategui R, Beltran B, Morales D, Capellino A, Desposorio C, Castillo J: The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru.
  • : e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined.
  • METHODS: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • Forty-four cases (92%) were diagnosed with non-Hodgkin lymphoma (NHL) and 4 cases (8%) with Hodgkin lymphoma (HL).
  • From the 44 NHL cases, 40 cases (91%) were of B-cell origin; 23 cases (57.5%) had diffuse large B-cell, 9 cases (22.5%) had Burkitt, 3 cases (7.5%) had plasmablastic, 2 cases (5%) had primary CNS, 2 cases (5%) had MALT and 1 case (2.5%) had primary effusion lymphoma.
  • The remaining 4 cases (9%) were of T-cell origin; 3 cases (75%) had peripheral T-cell lymphoma NOS and 1 case (25%) was ALK-negative anaplastic large cell lymphoma.
  • Also a high proportion of T-cells lymphomas are found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • In part this has been due to limited insights into the biology of this disease and the molecular mechanisms of oncogenesis.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic


36. Crosswell HE, Bergsagel DJ, Yost R, Lew G: Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatr Blood Cancer; 2008 Apr;50(4):883-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
  • Burkitt lymphoma is the most common AIDS-related lymphoma (ARL) in childhood.
  • We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy.
  • The combination of rituximab and chemotherapy with HAART therapy may be well-tolerated and effective in HIV/AIDS patients with Burkitt lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17278123.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


37. Yarchoan R, Tosato G, Little RF: Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol; 2005 Aug;2(8):406-15; quiz 423
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
  • Patients with HIV infection are at an increased risk of a number of malignancies, including Kaposi's sarcoma (KS) and certain B-cell lymphomas.
  • Most of these tumors are caused by oncogenic DNA viruses, including KS-associated herpesvirus and Epstein-Barr virus.
  • HIV contributes to the development of these tumors through several mechanisms, including immunodeficiency, immunodysregulation, and the effects of HIV proteins such as Tat.
  • The development of highly active antiretroviral therapy (HAART) has reduced the incidence of many HIV-associated tumors and has generally improved their responsiveness to therapy.
  • However, the number of people living with AIDS is increasing, and it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors will change as more people live longer with HIV infection.
  • By contrast, the goal of AIDS-related lymphoma therapy in most cases is the attainment of a complete response with curative intent, and the benefits of administering HAART during therapy must be weighed against possible disadvantages.
  • The past decade has seen substantial improvements in the treatment of AIDS-related lymphoma, which is attributed partially to a shift in tumor type and more effective regimens.
  • There is currently an interest in developing new therapies for HIV-associated malignancies, based on viral, vascular or other pathogenesis-based targets.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / complications. Neoplasms / drug therapy. Neoplasms / virology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / virology


38. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


39. Rothschild S, Dolder M, Seifert B, Lütolf UM, Ciernik IF: Radiation therapy for HIV-associated diffuse large cell non-Hodgkin lymphoma. J Int Assoc Physicians AIDS Care (Chic); 2009 Jul-Aug;8(4):239-48
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for HIV-associated diffuse large cell non-Hodgkin lymphoma.
  • PURPOSE: To report the clinical experience with external beam radiotherapy (RT) for AIDS-related lymphoma (ARL) with or without the involvement of the central nervous system (CNS) in HIV-infected patients.
  • PATIENTS AND METHODS: Clinical outcome of 24 HIV-seropositive patients with ARL treated with RT from 1995 to 2004 was reviewed, testing factors associated with outcome.
  • Radiotherapy dose was associated with survival in univariate (P = .04) and multivariate analysis (P = .01).
  • Other factors in univariate analysis associated with outcome were viral load (VL), highly active antiretroviral therapy (HAART), ARL stage, and CNS involvement.
  • [MeSH-major] Lymphoma, AIDS-Related / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Female. HIV Seropositivity. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Viral Load


40. Gujral S, Shet TM, Kane SV: Morphological spectrum of AIDS-related plasmablastic lymphomas. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological spectrum of AIDS-related plasmablastic lymphomas.
  • We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre.
  • Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL).
  • Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417882.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


41. Mounier N, Spina M, Gisselbrecht C: Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol; 2007 Mar;136(5):685-98
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern management of non-Hodgkin lymphoma in HIV-infected patients.
  • Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses.
  • This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL).
  • As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients.
  • Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229246.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 83
  •  go-up   go-down


42. Lamers SL, Fogel GB, McGrath MS: HIV-miR-H1 evolvability during HIV pathogenesis. Biosystems; 2010 Aug;101(2):88-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-miR-H1 evolvability during HIV pathogenesis.
  • Two early studies found no detectable miRNAs expressed within HIV; however, several studies have verified the existence and function of three HIV miRNAs, most notably HIV-miR-TAR, thus making the earlier results controversial.
  • Although miRNAs are highly conserved within most species, HIV is known to have a high mutation rate, which could contribute to the opposing experimental findings and raises questions about whether all HIV miRNAs are robust enough to maintain their integrity, especially in viral regions prone to insertions and deletions.
  • In addition, could the evolvability of HIV miRNAs contribute to the diversity in HIV disease pathogenesis?
  • To address this question, we examined mutations in 1293 sequences in a suspect HIV miRNA, called miR-H1, derived from a large variety of tissues from seven patients.
  • We also note a potential disease association between a less stable miR-H1 and the development of AIDS-related lymphoma (ARL).

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2008 Apr;36(7):2353-65 [18299284.001]
  • [Cites] PLoS Pathog. 2007 Nov;3(11):e163 [17983268.001]
  • [Cites] J Soc Biol. 2007;201(4):377-84 [18533098.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Retrovirology. 2008;5:112 [19077215.001]
  • [Cites] Mol Cell Biochem. 2009 Mar;323(1-2):143-8 [19082544.001]
  • [Cites] Drug News Perspect. 2008 Sep;21(7):369-81 [19259550.001]
  • [Cites] Retrovirology. 2009;6:18 [19220914.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Clin Infect Dis. 2009 Sep 1;49(5):780-6 [19622045.001]
  • [Cites] PLoS One. 2009;4(12):e8153 [19997510.001]
  • [Cites] J Med Virol. 2000 Jun;61(2):171-80 [10797371.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] J Hered. 2001 Jul-Aug;92(4):371-3 [11535656.001]
  • [Cites] J Virol. 2002 Apr;76(8):3852-64 [11907225.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):439-41 [12520045.001]
  • [Cites] Science. 2003 Mar 7;299(5612):1540 [12624257.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):150-7 [15207272.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] Nucleic Acids Res. 1997 Jan 1;25(1):1-6 [9016491.001]
  • [Cites] Clin Rev Allergy Immunol. 1996-1997 Winter;14(4):359-66 [9040966.001]
  • [Cites] Virology. 1997 Jun 9;232(2):319-31 [9191845.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):99-110 [9768617.001]
  • [Cites] J Gen Virol. 2005 Mar;86(Pt 3):751-5 [15722536.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Retrovirology. 2004;1:43 [15601472.001]
  • [Cites] Retrovirology. 2004;1:44 [15601474.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Virus Res. 2006 Nov;121(2):107-15 [16889864.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] BMC Mol Biol. 2007;8:63 [17663774.001]
  • [Cites] J Neurovirol. 2007 Aug;13(4):291-304 [17849313.001]
  • [Cites] PLoS Pathog. 2007 Sep 7;3(9):1281-90 [17907802.001]
  • [Cites] J Virol. 2007 Nov;81(22):12218-26 [17855543.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • (PMID = 20546828.001).
  • [ISSN] 1872-8324
  • [Journal-full-title] Bio Systems
  • [ISO-abbreviation] BioSystems
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066529; United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NCI NIH HHS / CA / U01 CA096230-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / HIV Envelope Protein gp120; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS407806; NLM/ PMC3478900
  •  go-up   go-down


43. Hill QA, Owen RG: CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev; 2006 Nov;20(6):319-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS prophylaxis in lymphoma: who to target and what therapy to use.
  • The purpose of this article is to review the current data on the risk of CNS relapse in patients with lymphoma and the efficacy of CNS directed prophylactic therapy.
  • CNS relapse occurred in 30-50% of those with Burkitt lymphoma and acute lymphoblastic leukaemia/lymphoma prior to the introduction of intensified regimens that include CNS prophylaxis.
  • Most patients with AIDS-related-lymphoma receive a short course of intrathecal prophylaxis but a re-evaluation of type and targeting of CNS prophylaxis is needed.
  • Patients with diffuse large B-cell lymphoma (DLBCL) have a 5% overall risk of CNS relapse but a high risk sub-population can be identified on the basis of raised LDH and >1 extranodal site, testicular or primary breast involvement.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / prevention & control. Lymphoma / complications. Lymphoma / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884838.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 151
  •  go-up   go-down


44. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study: Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther; 2007;12(6):931-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
  • OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.
  • METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.
  • We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.
  • Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months).
  • Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]).
  • The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


45. Navarro WH, Kaplan LD: AIDS-related lymphoproliferative disease. Blood; 2006 Jan 1;107(1):13-20
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoproliferative disease.
  • Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.
  • Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.
  • Typically, these individuals have presented with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.
  • Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.
  • Significant progress has been made in the understanding and management of ARL but outcomes still remain inferior compared to those achieved in HIV- individuals.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099881.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


46. Navarro JT, Hernández A, Rodríguez-Manzano J, Mate JL, Grau J, Morgades M, Martró E, Tural C, Ribera JM, Matas L: Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients. Med Clin (Barc); 2010 Oct 9;135(11):485-90
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients.
  • BACKGROUND AND OBJECTIVES: To assess the use of the Epstein-Barr virus (EBV) viral load as a marker for lymphoma diagnosis in HIV-infected patients.
  • We also aimed to identify the relationship between EBV viral load in plasma and the presence of EBV in lymphoma cells.
  • PATIENTS AND METHODS: Retrospective observational study of two HIV-infected populations: one of patients diagnosed with lymphoma and a control group.
  • Thirty-nine patients with AIDS-related lymphoma (ARL) (32 non-Hodgkin's and 7 Hodgkin's lymphomas) and 134 HIV-positive individuals without neoplasia or opportunistic infections were studied.
  • Blood samples were collected before lymphoma treatment in ARL patients.
  • EBV viral load was measured in plasma by real-time quantitative PCR and the presence of EBV-EBER mRNA in lymphoma tumor was investigated by in situ hybridization.
  • RESULTS: Patients with ARL had higher EBV viral loads than those without lymphoma: 24,180.5 (±73,387.6)copies/mL versus 2.6 (±21.6)copies/mL (p<0.001).
  • HIV-infected patients without lymphoma had negative or very low EBV load values.
  • Among ARL patients, no correlation was found between EBV viral loads and CD4+ lymphocyte counts or between EBV and HIV RNA loads, or any other clinical or biological parameter.
  • Cases with an EBV-EBER-positive lymphoma had higher EBV viral loads than those with EBER-negative tumors.
  • CONCLUSIONS: EBV viral load is a useful marker of lymphoma in HIV-infected patients, and may be a useful tool for early diagnosis and treatment.
  • [MeSH-major] Herpesvirus 4, Human. Lymphoma, AIDS-Related / blood. Lymphoma, AIDS-Related / diagnosis. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20673682.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


47. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C: AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood; 2006 May 15;107(10):3832-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
  • We aimed to compare AIDS risk-adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART).
  • A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4(+) cell counts below 0.10 x 10(9)/L (100/mm(3)).
  • A total of 218 good-risk patients (HIV score 0) received ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone) or CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone); 177 intermediate-risk patients (HIV score 1), CHOP or low-dose CHOP (Ld-CHOP); and 90 poor-risk patients (HIV score 2-3), Ld-CHOP or VS (vincristine and steroid).
  • The time-dependent Cox model demonstrated that the only significant factors for OS were HAART (relative risk [RR] 1.6, P < .001), HIV score (RR 1.7, P < .001), and the International Prognostic Index (IPI) score (RR 1.5, P < .001) but not chemotherapy regimen.
  • Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2006 Nov 15;108(10):3621; author reply 3621-2 [17085718.001]
  • (PMID = 16410446.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


48. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF: AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis; 2008;18(2 Suppl 2):S2-189-94
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.
  • INTRODUCTION: Malignant disorders have been linked to the HIV epidemic from its onset.
  • Implementation of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the HIV/AIDS morbidity and mortality.
  • METHODS: A cross-sectional study was conducted in 171 HIV-infected adults who were followed in Puerto Rico from May 1992 through December 2005.
  • Neoplasm prevalence was measured, and the difference in AIDS- and non-AIDS-defining neoplasms was analyzed before and after the HAART era.
  • Of these, 51.5% were AIDS-defining neoplasms, and 68% were established before HAART.
  • AIDS-defining neoplasms accounted for 62.4% of those detected before the availability of HAART and 25.9% of those detected after HAART.
  • Except for cervical carcinoma, the prevalence of AIDS-defining neoplasms decreased after HAART.
  • Non-AIDS lymphomas and prostate neoplasms were more frequent after HAART.
  • DISCUSSION: Our study found a significant reduction of Kaposi sarcoma and AIDS-related lymphoma in the HAART era of the AIDS epidemic.
  • A higher prevalence of non-AIDS-defining lymphomas, prostate carcinoma, and cervical carcinoma was seen in the HAART era.
  • Preventive strategies that include screening tests, vaccination, and lifestyle modification should be routinely applied in HIV-infected patients.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2006 Nov;61(11):1000-8 [17071836.001]
  • [Cites] MMWR Suppl. 1987 Aug 14;36(1):1S-15S [3039334.001]
  • [Cites] J Behav Med. 2007 Oct;30(5):371-83 [17570050.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2417-9 [16735700.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):223-8 [10889597.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):480-2 [11391169.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Oct 17;17(15):2227-36 [14523280.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-57-62 [16312941.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):1030-8 [12684916.001]
  • (PMID = 18646347.001).
  • [ISSN] 1049-510X
  • [Journal-full-title] Ethnicity & disease
  • [ISO-abbreviation] Ethn Dis
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / G12 MD007583; United States / NCRR NIH HHS / RR / U54 RR019507; United States / NCRR NIH HHS / RR / G12RR03035; United States / NCRR NIH HHS / RR / 1U54RR01950701; United States / NCRR NIH HHS / RR / G12 RR003035
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS425729; NLM/ PMC3546505
  •  go-up   go-down


49. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma; 2005 Feb;46(2):207-15
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
  • Non-Hodgkin's lymphoma is an AIDS-defining disease.
  • We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
  • The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.
  • Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621803.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


50. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • HIV-infected macrophages are a known viral reservoir and have been shown to have lymphomagenic potential in SCID mice; therefore, there is an interest in determining if a viral component to lymphomagenesis also exists.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).
  • 1) high-resolution phylogenetic analysis showed a significant degree of compartmentalization between lymphoma and non-lymphoma viral sub-populations while viral sub-populations from lymph nodes appeared to be intermixed within sequences from tumor and non-tumor tissues, 2) a 100-fold increase in the effective HIV population size in tumor versus non-tumor tissues was associated with the emergence of lymphadenopathy and aggressive metastatic ARL, and 3) HIV gene flow among lymph nodes, normal and metastatic tissues was non-random.
  • The different population dynamics between the viruses found in tumors versus the non-tumor associated viruses suggest that there is a significant relationship between HIV evolution and lymphoma pathogenesis.
  • Moreover, the study indicates that HIV could be used as an effective marker to study the origin and dissemination of lymphomas in vivo.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


51. NAGAI Y, MORI M, INOUE D, KIMURA T, SHIMOJI S, TOGAMI K, TABATA S, MATSUSHITA A, NAGAI K, Imai Y, Takafuta T, Takahashi T: Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma. Rinsho Ketsueki; 2009 Nov;50(11):1641-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma.
  • A 62-year-old man was diagnosed with human immunodeficiency virus (HIV) infection while suffering from recurrent herpes zoster infection.
  • Laboratory examination revealed CD4(+) lymphocyte count 16 cells/mul and HIV loading 150,000 copies/ml at presentation.
  • Histologic diagnosis of a biopsied lymph node was diffuse, large, B cell-type malignant lymphoma.
  • The karyotype of the lymphoma cells was t(8;14)(q24;q32), which was confirmed by G-banding and fluorescent in situ hybridization.
  • The clinical stage of the lymphoma was IVB and the international prognosis index was categorized as high.
  • Complete remission (CR) of the lymphoma was obtained after 2 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) chemotherapy and 4 subsequent courses of rituximab-combined CHOP (R-CHOP).
  • Because of the poor prognosis of AIDS-related lymphoma, he received autologous peripheral blood stem cell transplantation with the MEAM protocol (ranimustine, etoposide, cytarabine, melphalan) as a conditioning procedure without a severe infectious episode.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009441.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


52. Lamers SL, Salemi M, Galligan DC, Morris A, Gray R, Fogel G, Zhao L, McGrath MS: Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol; 2010 May;16(3):230-41
LANL HIV Databases. LANL HIV Databases .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain.
  • The interplay between pathology and human immunodeficiency virus (HIV) expansion in brain tissues has not been thoroughly assessed in the highly active antiretroviral therapy (HAART) era.
  • HIV-associated dementia (HAD) is marked by progressive brain infection due to recruitment and migration of macrophages in brain tissues; however, the cellular and viral events occurring prior to HAD development and death are under debate.
  • In this study, 66 brain tissues from 11 autopsies were analyzed to assess HIV-1 DNA concentration in brain tissues.
  • In most patients without HAD, it was impossible to amplify HIV-1 from brain tissues.
  • (1) cardiovascular disease, a disease associated with HAART therapy;.
  • (2) bacterial infections, including Mycobacterium avium complex, rapid occurrence of extreme dementia; and (3) acquired immunodeficiency syndrome (AIDS)-related lymphoma with meningeal involvement.
  • HIV-1 DNA was also amplified from multiple tissues of two HAD patients.
  • Analysis of HIV-1 nef, gp120, and gp41 sequences showed reduced viral evolution within brain tissues for the non-HAD cases relative to patients with clinical and histological HAD.
  • The present study is the first to show a potential correlation between HIV-1 evolutionary patterns in the brain and different neuropathologies.

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Symptom Management .
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • HIV InSite. treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1999 Oct 22;13(15):2055-9 [10546857.001]
  • [Cites] Glia. 2009 May;57(7):734-43 [18985732.001]
  • [Cites] J Leukoc Biol. 2000 Sep;68(3):303-10 [10985244.001]
  • [Cites] Clin Infect Dis. 2000 Dec;31(6):1488-92 [11096017.001]
  • [Cites] J Clin Microbiol. 2001 Jan;39(1):298-303 [11136787.001]
  • [Cites] Neurology. 2001 Jan 23;56(2):257-60 [11160967.001]
  • [Cites] J Exp Med. 2001 Apr 16;193(8):905-15 [11304551.001]
  • [Cites] Circulation. 2001 Jul 17;104(3):257-62 [11457741.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):542-4 [11502933.001]
  • [Cites] Annu Rev Neurosci. 2002;25:537-62 [12052920.001]
  • [Cites] Am Heart J. 2002 Oct;144(4):642-8 [12360160.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Lancet. 2002 Nov 30;360(9347):1747-8 [12480430.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:115-21 [12491162.001]
  • [Cites] J Virol. 2003 Nov;77(22):12336-45 [14581570.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S35-40 [14704742.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Circulation. 2004 Apr 6;109(13):1603-8 [15023877.001]
  • [Cites] J Virol. 1993 Sep;67(9):5623-34 [8350415.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):76-82 [8033423.001]
  • [Cites] Ann Neurol. 1995 Nov;38(5):755-62 [7486867.001]
  • [Cites] AIDS. 1995 Sep;9(9):1001-8 [8527071.001]
  • [Cites] Ann Neurol. 1996 Mar;39(3):392-5 [8602761.001]
  • [Cites] Nature. 1996 Jun 20;381(6584):661-6 [8649511.001]
  • [Cites] Science. 1996 Jun 28;272(5270):1955-8 [8658171.001]
  • [Cites] Clin Rev Allergy Immunol. 1996-1997 Winter;14(4):359-66 [9040966.001]
  • [Cites] J Virol. 1998 Mar;72(3):2509-15 [9499115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12574-9 [9770527.001]
  • [Cites] J Infect Dis. 1999 May;179 Suppl 3:S457-60 [10099119.001]
  • [Cites] J Neuroimmunol. 1999 Aug 3;98(2):185-200 [10430052.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):69-81 [15630430.001]
  • [Cites] Curr HIV Res. 2005 Jan;3(1):53-60 [15638723.001]
  • [Cites] Neurotox Res. 2004;6(7-8):503-21 [15639783.001]
  • [Cites] Virus Res. 2005 Aug;111(2):194-213 [15885841.001]
  • [Cites] J Neurovirol. 2005 Apr;11(2):107-28 [16036790.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Expert Rev Mol Med. 2005 Dec 2;7(27):1-26 [16321172.001]
  • [Cites] Am Heart J. 2006 Jun;151(6):1147-55 [16781213.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [16878047.001]
  • [Cites] J Virol. 2007 Jun;81(12):6643-51 [17428864.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] Int Rev Psychiatry. 2008 Feb;20(1):3-13 [18240058.001]
  • [Cites] IEEE/ACM Trans Comput Biol Bioinform. 2008 Apr-Jun;5(2):291-300 [18451438.001]
  • [Cites] J Neurovirol. 2008 Aug;14(4):318-26 [18780233.001]
  • [Cites] Curr HIV Res. 2008 Sep;6(5):388-400 [18855649.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] J Infect Dis. 2000 Apr;181(4):1486-90 [10762582.001]
  • (PMID = 20367240.001).
  • [ISSN] 1538-2443
  • [Journal-full-title] Journal of neurovirology
  • [ISO-abbreviation] J. Neurovirol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066529-12; United States / NICHD NIH HHS / HD / HD32259; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NIMH NIH HHS / MH / MH073510-01; United States / NIMH NIH HHS / MH / R01 MH073510; United States / NCI NIH HHS / CA / U01 CA066529; United States / NIMH NIH HHS / MH / R01 MH073510-01; United States / NICHD NIH HHS / HD / R01 HD032259; United States / NIAID NIH HHS / AI / AI065265; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NINDS NIH HHS / NS / R01 NS063897
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120; 0 / HIV Envelope Protein gp41; 0 / Human Immunodeficiency Virus Proteins; 0 / gp120 protein, Human immunodeficiency virus 1; 0 / nef Gene Products, Human Immunodeficiency Virus; 0 / nef protein, Human immunodeficiency virus 1; 0 / p24 protein, Human Immunodeficiency Virus Type 1
  • [Other-IDs] NLM/ NIHMS225058; NLM/ PMC2994721
  •  go-up   go-down


53. Fellows IM, Schwaebe M, Dexheimer TS, Vankayalapati H, Gleason-Guzman M, Whitten JP, Hurley LH: Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity. Mol Cancer Ther; 2005 Nov;4(11):1729-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psorospermin is a natural product that has been shown to have activity against drug-resistant leukemia lines and AIDS-related lymphoma.
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols. Body Weight. Cell Line. Cell Line, Tumor. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Epoxy Compounds / chemistry. In Vitro Techniques. Inhibitory Concentration 50. Leukemia / drug therapy. Lymphoma / drug therapy. Mice. Mice, Nude. Models, Chemical. Models, Molecular. Stereoisomerism. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275994.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA49751
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / Xanthones; 0W860991D6 / Deoxycytidine; 74045-97-9 / psorospermin; 9007-49-2 / DNA; B76N6SBZ8R / gemcitabine; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


54. Tanaka PY, Pracchia LF, Bellesso M, Chamone DA, Calore EE, Pereira J: A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil. Ann Hematol; 2010 Jan;89(1):45-51
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil.
  • The aim of this study was to evaluate a prognostic score for aids-related lymphoma (ARL).
  • Diffuse large B-cell lymphoma (DLBC) was the most observed histological type (79.8%).
  • The median CD4 lymphocyte count at lymphoma diagnosis was 125 cells per microliter.
  • The survival risk factors observed in multivariate analysis (previous AIDS and high-intermediate/high international prognostic index (IPI)) were combined to construct a risk score, which divided the whole patient population in three distinct groups as low, intermediate, and high risk.
  • Median disease-free survival (DFS) for patients that achieved CR was not reached, and DFS in 4 years was 83.0%.
  • Our results show that the reduced OS observed could be explained by poor immune status with advanced stage of disease seen in our population of HIV-positive patients.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2007 Mar 23;128(6):1173-86 [17382885.001]
  • [Cites] Br J Haematol. 2007 Mar;136(5):762-4 [17313379.001]
  • [Cites] J Thromb Haemost. 2006 Dec;4(12):2656-63 [16961585.001]
  • [Cites] Br J Haematol. 2006 Apr;133(1):78-82 [16512832.001]
  • [Cites] Eur J Haematol. 2002 May;68(5):253-61 [12144531.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):155-60 [15630455.001]
  • [Cites] Platelets. 2008 Mar;19(2):96-103 [18297548.001]
  • [Cites] Transfus Apher Sci. 2003 Jun;28(3):285-95 [12725956.001]
  • [Cites] Blood. 2003 May 1;101(9):3708-13 [12506021.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1658-9; author reply 1659 [12560247.001]
  • [Cites] Lab Invest. 2009 Apr;89(4):374-84 [19238135.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):494-7 [18492095.001]
  • [Cites] J Thromb Haemost. 2008 Oct;6(10):1780-8 [18665919.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 23;320(2):303-10 [15219827.001]
  • (PMID = 19495752.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2900585
  •  go-up   go-down


55. Pippi F: A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation. Med Hypotheses; 2008;70(2):291-3
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
  • Highly active antiretroviral therapy dramatically decreases in vivo viral replication to levels below the level of clinical detection, but does not eradicate HIV-1 infection on the basis of persistent low-level or cryptic viral replication and latent provirus in resting CD4+ T lymphocytes.
  • Autologous hematopoietic cell transplantation now appears as a safe, feasible, and reasonable approach for Aids-related lymphoma in patients who meet criteria for transplantation.
  • The hypothesis is based on the possibility that hematopoietic stem cells from a HIV-positive patient could be collected before the patient becomes infected with HIV.
  • The following transplantation of the autologous hematopoietic stem cells, collected before HIV infection, would allow the complete recovery.
  • Although hematopoietic stem cells from man before infection with HIV are unlikely to be available, a successful test on the animal would suggest a new approach which could allow the cure of HIV in future.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV Infections / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Animals. Combined Modality Therapy. HIV-1 / drug effects. HIV-1 / physiology. Humans. Models, Biological. Transplantation Conditioning. Transplantation, Autologous. Virus Replication / drug effects

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681707.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


56. Lascaux AS, Hemery F, Goujard C, Lesprit P, Delfraissy JF, Sobel A, Lepage E, Lévy Y: Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res Hum Retroviruses; 2005 Mar;21(3):214-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas.
  • The influence of HAART on the survival of patients with AIDS-related lymphoma (ARL) was evaluated.
  • A retrospective analysis of 73 HIV-1-infected patients with proven ARL diagnosed between 1992 and 2000 was conducted.
  • At diagnosis of ARL, the median age was 37 years and 22 patients (30%) had prior AIDS-defining events.
  • There was no statistical significant differences in lymphoma extensive stage, presence of B symptoms, meningeal involvement, CD4 cell count at diagnosis, prior AIDS events, or chemotherapy regimens between the two groups.
  • No influence on outcome was found for other variables except for prior AIDS and bone marrow involvement.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / mortality

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795527.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.
  • Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.
  • Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.
  • These findings were not related to age, sex or type of lymphoma.
  • There was no association of HHV-8 with the lymphoma cells.
  • CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


58. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.
  • Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.
  • Although the overall median survival was similar for both groups in the pre-HAART era (HIV-BL, 6.4 months v HIV-DLCL, 8.3 months; P = .43), survival was significantly worse in patients with HIV-BL in the HAART era (HIV-BL, 5.7 months v HIV-DLCL, 43.2 months; P = .0003).
  • In comparison, histology of HIV-BL and no attainment of complete remission were independent poor prognostic factors in the HAART era.
  • CONCLUSION: Survival of patients with HIV-DLCL has improved in the HAART era, along with CD4 count, whereas survival of similarly treated patients with HIV-BL remained poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Nov 20;23(33):8538-40; author reply 8540-1 [16293885.001]
  • [CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]
  • (PMID = 15883411.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol
  •  go-up   go-down


59. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • This is mostly explained by the paucity of supportive care compounded by wasting and inanition attributable to advanced cancer and HIV infection making patients more susceptible to myelosuppressive side effects of cytotoxic chemotherapy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


60. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene; 2005 Mar 24;24(13):2121-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
  • The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).
  • ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems.
  • Downmodulation of the ERK1/2 and NF-kappa B pathways inhibits the transcriptional activity of AP-1 and NF-kappa B transcription factors, respectively, both of which lead to the downregulation of Bcl-(xL) (Bcl-2 related gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Signal Transduction / drug effects


61. Wolach O, Bairey O, Lahav M: Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore); 2010 Sep;89(5):308-18
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab is a chimeric monoclonal antibody against CD20 that is used mainly for the treatment of CD20-positive lymphoma.
  • Four patients were treated for diffuse large B-cell lymphoma, and 2 patients for follicular lymphoma.
  • One patient presented with LON and concomitant subacute pulmonary disease that was attributed to rituximab therapy.In addition to our own case series we present a systematic review of the literature, which we performed to compile data to describe better the syndrome of LON.
  • Data regarding populations at risk are not consistent, and in some instances are conflicting.Patients considered at increased risk of LON include patients after autologous stem cell transplantation, patients treated for acquired immunodeficiency syndrome (AIDS)-related lymphoma, and patients treated with purine analogues.
  • In addition, advanced stages of disease and having received multiple doses of rituximab are risk factors for LON.The mechanism of LON is poorly understood.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827108.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


62. Bibas M, Antinori A: EBV and HIV-Related Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV and HIV-Related Lymphoma.
  • HIV-associated lymphoproliferative disorders represent a heterogeneous group of diseases, arising in the presence of HIV-associated immunodeficiency.
  • The overall prevalence of HIV-associated lymphoma is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1).
  • Moreover, they still represent one of the most frequent cause of death in HIV-infected patients.
  • Epstein-Barr virus (EBV), a γ-Herpesviruses, is involved in human lymphomagenesis, particularly in HIV immunocompromised patients.
  • It has been largely implicated in the development of B-cell lymphoproliferative disorders as Burkitt lymphoma (BL), Hodgkin disease (HD), systemic non Hodgkin lymphoma (NHL), primary central nervous system lymphoma (PCNSL), nasopharyngeal carcinoma (NC).
  • Virus-associated lymphomas are becoming of significant concern for the mortality of long-lived HIV immunocompromised patients, and therefore, research of advanced strategies for AIDS-related lymphomas is an important field in cancer chemotherapy.
  • Detailed understanding of the EBV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy The linkage of HIV-related lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]
  • [Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1731-41 [11748275.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]
  • [Cites] AIDS. 2002 May 24;16(8):1195-6 [12004285.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15572-7 [12434018.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] J Virol. 1996 Feb;70(2):1143-53 [8551575.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):373-6 [9026061.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] Neurology. 2000 Feb 22;54(4):993-7 [10691003.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):911-8 [9462239.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]
  • [Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]
  • [Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Neurology. 1997 Mar;48(3):687-94 [9065549.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Presse Med. 2004 Dec 4;33(21):1487-92 [15637794.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):61-7 [16216037.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] Blood Rev. 2008 Sep;22(5):261-81 [18456377.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]
  • [Cites] AIDS. 1997 Oct;11(12):1522-3 [9342077.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):364-9 [9498486.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Dermatology. 2004;208(3):287-90 [15118393.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]
  • (PMID = 21416008.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033170
  •  go-up   go-down


63. Vaghefi P, Martin A, Prévot S, Charlotte F, Camilleri-Broët S, Barli E, Davi F, Gabarre J, Raphael M, Poirel HA: Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status. AIDS; 2006 Nov 28;20(18):2285-91
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.
  • BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.
  • Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.
  • DNA-CNC tended to be more frequent in EBV-positive lymphomas with latency type II/III than in EBV-positive latency I or EBV-negative lymphomas.
  • Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.
  • The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117014.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


64. Balsalobre P, Díez-Martín JL, Re A, Michieli M, Ribera JM, Canals C, Rosselet A, Conde E, Varela R, Cwynarski K, Gabriel I, Genet P, Guillerm G, Allione B, Ferrant A, Biron P, Espigado I, Serrano D, Sureda A: Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol; 2009 May 1;27(13):2192-8
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem-cell transplantation in patients with HIV-related lymphoma.
  • PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure.
  • Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT.
  • RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18).
  • At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease.
  • CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3).
  • Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively).
  • CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263
  • (PMID = 19332732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L: T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation; 2005 Sep 15;80(5):673-82
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
  • BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.
  • Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.
  • METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
  • CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transplantation. 2006 Jun 27;81(12):1752-3 [16794547.001]
  • (PMID = 16177644.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


66. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ: Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci; 2007 Oct;334(4):317-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease masquerading as HIV-related lymphoma.
  • Patients with human immunodeficiency virus (HIV) infection are at increased risk for developing lymphoproliferative disorders.
  • Multicentric Castleman's disease should always be kept in the differential diagnosis of HIV-positive patients suspected of having lymphoma to avoid misdiagnosis.
  • We report the case of a 40-year-old HIV-positive homosexual man who presented with lower back pain and features highly suggestive of lymphoma including lymphadenopathy, elevated lactic dehydrogenase, and splenomegaly.
  • The patient's plasma was positive by polymerase chain reaction for Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/ HHV8), and a lymph node biopsy revealed Multicentric Castleman's disease.
  • Albeit a rare condition, Castleman's disease should always be considered in immunocompromised patients suspected of having lymphoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Lymphoma, AIDS-Related / diagnosis


67. Madan RA, Chang VT, Dever LL: An uncommon presentation of HIV-related lymphoma. AIDS Patient Care STDS; 2007 Jul;21(7):443-6
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of HIV-related lymphoma.
  • Although highly active antiretroviral therapy has improved the clinical course of patients with HIV, this population remains at a significantly increased risk for non-Hodgkin's lymphoma (NHL).
  • We encountered a patient with HIV-related NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / virology. Spinal Cord Compression / etiology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651024.001).
  • [ISSN] 1087-2914
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Sparano JA: HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol; 2007 Sep;19(5):458-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphoma: the evidence for treating aggressively but with caution.
  • PURPOSE OF THE REVIEW: The aim of this article is to review key reports regarding the biology and management of HIV-associated lymphoma during the past year.
  • RECENT FINDINGS: The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased risk of Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • Emerging evidence suggests that patients with HIV-associated lymphoma should be treated in a similar manner as immunocompetent patients with the same disease, especially if the CD4 count is 50-100 cells/mul or higher.
  • Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy appears to result in improved control of B-cell lymphoma, but may come at the expense of an increased risk of bacterial and viral infections.
  • SUMMARY: Although the evidence currently supports an aggressive and curative approach for the management of HIV-associated lymphoma, clinicians must be vigilant about implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] HIV. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


69. Bedoya F, Medveczky MM, Lund TC, Perl A, Horvath J, Jett SD, Medveczky PG: Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leuk Res; 2009 Nov;33(11):1499-504
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines.
  • Since most oncogenic viruses persist as extrachromosomal covalently closed circular DNA (cccDNA) in tumor cells, we developed an assay to visualize and identify cccDNA in primary lymphomas.
  • One AIDS-associated lymphoma (EL) was further studied in detail as its mitochondrial genome consisted of tandem head-to-tail duplications.
  • Insertion of C-residues was noted near the origin of replication of EL mtDNA.
  • EL cells responded weakly to Fas-apoptotic stimulus, displayed reduced mitochondrial activity and mass, and produced higher levels of reactive oxygen intermediates.
  • Screening of several AIDS-associated lymphomas and established lymphoid cell lines also revealed the presence of mitochondrial genome concatemers consisting of interlinked monomer molecules.
  • Taken together, our results suggest that formation of mtDNA concatemers is associated with oncogenic transformation in lymphoid cells.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14453-8 [18796602.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] IUBMB Life. 2003 Apr-May;55(4-5):213-7 [12880201.001]
  • [Cites] Mol Genet Genomics. 2003 Jul;269(4):454-63 [12768414.001]
  • [Cites] Science. 2004 May 14;304(5673):981 [15143273.001]
  • [Cites] Biopolymers. 1970;9(3):373-9 [5417647.001]
  • [Cites] J Virol. 1984 Apr;50(1):248-54 [6321792.001]
  • [Cites] J Virol. 1989 Sep;63(9):3601-11 [2547988.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Dec;38(12):2743-9 [7695256.001]
  • [Cites] Nucleic Acids Res. 1996 Oct 15;24(20):4084-91 [8918816.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172-6 [9037025.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] Nucleic Acids Res. 1998 Feb 15;26(4):967-73 [9461455.001]
  • [Cites] Biochem Z. 1962;336:281-98 [14003030.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):700-7 [16782042.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:363-74 [16869773.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4647-62 [16892079.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] J Infect Dis. 2007 May 15;195(10):1419-25 [17436221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):9001-6 [17517629.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4331-5 [17671113.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Methods Mol Biol. 2007;372:153-66 [18314724.001]
  • [Cites] Cancer Lett. 2008 Jul 18;266(1):30-6 [18372105.001]
  • [Cites] Cancer Lett. 2008 Jul 18;266(1):21-9 [18374479.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):789-95 [11048730.001]
  • (PMID = 19362738.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111196-04; United States / NCI NIH HHS / CA / CA111196-02; United States / NCI NIH HHS / CA / R01CA111196; United States / NCI NIH HHS / CA / R01 CA111196-01A2; United States / NCI NIH HHS / CA / CA111196-03; United States / NCI NIH HHS / CA / R01 CA111196-03; United States / NCI NIH HHS / CA / CA111196-04; United States / NCI NIH HHS / CA / R01 CA111196; United States / NCI NIH HHS / CA / R01 CA111196-02; United States / NCI NIH HHS / CA / CA111196-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ NIHMS103972; NLM/ PMC2730422
  •  go-up   go-down


70. Spina M, Tirelli U: Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol; 2005 Sep;17(5):462-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
  • PURPOSE OF REVIEW: This review discusses the potential benefits and risks of using the anti-CD20 monoclonal antibody rituximab for the treatment of HIV-associated B-cell non-Hodgkin's lymphoma.
  • RECENT FINDINGS: Studies have consistently demonstrated that rituximab improves response and survival when combined with standard chemotherapy compared with chemotherapy alone in immunocompetent patients with intermediate-grade non-Hodgkin's lymphoma.
  • Several recently reported phase II and III trials have evaluated the use of rituximab plus chemotherapy for HIV-associated B-cell non-Hodgkin's lymphoma.
  • Phase II trials combining rituximab with either standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy or infusional chemotherapy have reported encouraging results, suggesting a similar benefit in HIV-positive individuals.
  • A phase III trial comparing CHOP with CHOP-plus rituximab (R-CHOP) demonstrated a lower risk from progression of the lymphoma, but a higher risk of early and late infectious-related death in patients with a low CD4 count (< 50/microL).
  • SUMMARY: Rituximab should be used cautiously in patients with advanced HIV infection who have a CD4 count of less than 50/microL, as it seems to increase the risk of developing fatal infectious complications.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093796.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 19
  •  go-up   go-down


71. Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P: Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses; 2010 Feb;26(2):245-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
  • The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
  • HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
  • At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
  • HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
  • Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
  • Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load


72. Leiggener CS, Kunz Ch, Lohri A, Fridrich K, Honigmann K: [HIV-associated lymphoma -- an unusual cause of pathological mandibular fracture]. Mund Kiefer Gesichtschir; 2005 Jan;9(1):48-52
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-associated lymphoma -- an unusual cause of pathological mandibular fracture].
  • [Transliterated title] HIV-assoziiertes Lymphom -- ungewöhnliche Ursache einer pathologischen Unterkieferfraktur. Fallbericht und Behandlungsoptionen bei Immundefizienz.
  • Despite the introduction of highly active antiretroviral therapy (HAART), diffuse large B-cell lymphoma (DLBCL) remains a common malignancy in human immunodeficiency virus (HIV)-infected patients, especially the plasmablastic variant.
  • About 50% of lymphomas in HIV patients are extranodal and half of them occur in the head and neck area.
  • We report the case of a 52-year-old patient with a known HIV infection and fracture of the angular region of the mandible.
  • A biopsy performed at the time of revision revealed the diagnosis of a primary lymphoma in the mandible.
  • After chemotherapy had induced complete remission of the lymphoma and autogenous iliac crest bone grafting had been performed the fracture united.
  • Primary lymphoma in the mandible is a disease that presents with a nonspecific radiological appearance which may mimic osteomyelitis or periodontal pathology.
  • In our experience HIV-positive patients with mandibular fracture should be treated according to the guidelines established for HIV-negative patients.
  • [MeSH-major] Fractures, Spontaneous / diagnosis. Lymphoma, AIDS-Related / diagnosis. Mandibular Fractures / diagnosis. Mandibular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688241.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


73. Valenzuela AA, Walker NJ, Sullivan TJ: Plasmablastic lymphoma in the orbit: case report. Orbit; 2008;27(3):227-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma in the orbit: case report.
  • Plasmablastic lymphoma (PBL) is a rare entity most commonly identified in the oral cavity of immunodeficient patients.
  • We describe a case of atypical rapidly progressive pre-septal brawny induration affecting the right orbit in a patient with HIV-related lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / methods. Biopsy, Needle. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Risk Assessment. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569836.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B: [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era]. Epidemiol Prev; 2009 Jul-Oct;33(4-5):184-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
  • [Transliterated title] AIDS e tossicodipendenza: determinanti della sopravvivenza nell'era delle terapie antiretrovirali altamente efficaci.
  • OBJECTIVES: to estimate survival, after AIDS diagnosis, in people who got infected with HIV through injecting drug use (IDUs), to identify among variables collected at AIDS diagnosis those which were associated to prognosis and to assess the frequency of morbid conditions at death.
  • SETTING AND PARTICIPANTS: 4,040 IDUs diagnosed with AIDS in Italy between 1999 and 2005.
  • RESULTS: the 2-year and 5-year survival probabilities after AIDS diagnosis of IDUs were 72% and 60%, respectively.
  • Elevated risks of death emerged for IDUs with older ages (HR=2.0 95% CI 1.6-2.4 for>45 years old vs.<35 years old), lower education (HR=1.4 95% CI 1.2-1.7 for elementary school vs. high school/university), longer time span between first HIV positive test and AIDS diagnosis (HR=1.6 95% CI 1.4-1.9 for > 6 months vs. < 6 months), and lower CD4 cell count at diagnosis (HR=1.5 95% CI 1.3-1.7 for <50 cells/mm3 vs. > 200 cells/mm3).
  • Compared to Pneumocystis carinii pneumonia, non-Hodgkin lymphomas were the worst prognostic factors, particularly primary brain lymphoma (HR=7.2, 95% CI 4.4-11.8).
  • 52% of cases reported no AIDS-defining illnesses: 64 (4%) violent causes, 94 (6%) cancers, and 656 (42%) only non neoplastic illnesses, among which 415 (27%) liver diseases.
  • CONCLUSION: the results of this population-based study showed that, in the highly active antiretroviral therapy era, survival of IDUs with AIDS was still lower compared to that of HIV sexual transmission groups.
  • The presence at death, in 52% of cases, of non AIDS-defining illnesses indicates the important role on mortality of co-morbidities, including liver diseases and violent causes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / mortality. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Substance Abuse, Intravenous / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Age Factors. Comorbidity. Death Certificates. Educational Status. Equipment Contamination. HIV Infections / transmission. Homicide / statistics & numerical data. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Liver Diseases / mortality. Lymphoma, AIDS-Related / mortality. Medical Record Linkage. Needles. Proportional Hazards Models. Registries. Retrospective Studies. Risk. Sexual Behavior

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124634.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


75. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).
  • As patients survive longer, long-term therapy-related complications take on greater importance.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.
  • Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


76. Kloska SP, Husstedt IW, Schlegel PM, Anneken K, Evers S, Fischbach R, Heindel W: [Magnetic resonance imaging findings of the brain in adult HIV and AIDS patients]. Rofo; 2008 Jan;180(1):21-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging findings of the brain in adult HIV and AIDS patients].
  • [Transliterated title] Magnetresonanztomografische Befunde des Gehirns bei adulten Patienten mit HIV und AIDS.
  • The spectrum of pathology affecting the central nervous system (CNS) in patients suffering from acquired immunodeficiency syndrome (AIDS) includes not only the human immunodeficiency virus (HIV) infection itself but also opportunistic infections and tumors secondary to AIDS.
  • Despite progress in antiretroviral therapy and the subsequent decrease in the incidence of associated diseases, opportunistic infections and tumors secondary to the HIV infection continue to be the limiting factor in terms of survival with AIDS.
  • Magnetic resonance imaging is often the diagnostic method of choice in suspected CNS pathology of HIV patients.
  • In the following, the typical clinical and radiological features of several AIDS-related pathologies are presented and discussed.
  • [MeSH-major] AIDS Dementia Complex / diagnosis. AIDS-Related Opportunistic Infections / diagnosis. Acquired Immunodeficiency Syndrome / diagnosis. Brain / pathology. Brain Neoplasms / diagnosis. HIV Infections / diagnosis. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningoencephalitis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukoencephalopathy, Progressive Multifocal / diagnosis. Lymphoma, AIDS-Related / diagnosis. Sarcoma, Kaposi / diagnosis


77. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • Recent descriptions of long-term remissions in patients with posttransplantation EBV-associated PCNSL who received EBV-specific therapy suggest some antitumor effect is anti-EBV mediated.
  • PATIENTS AND METHODS: We enrolled 4 patients with AIDS-related PCNSL into a novel antiviral and immunomodulatory protocol.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • CONCLUSION: We conclude that for patients with AIDS and PCNSL, treatments with dual efficacy against HIV and EBV merit further investigation.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality


78. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas in Nigeria.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • However, HIV/AIDS epidemics appear not to have been associated with higher incidence of lymphomas in Africa.
  • We therefore carried out this study to highlight the significance or otherwise of HIV/AIDS epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.
  • Since January 1993 to the present, all patients with haematologic cancers are routinely screened (following appropriate counseling) for HIV infection.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • Those patients confirmed to be HIV/AIDS positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • Nine patients (2.3%) were confirmed to be HIV- positive, all within the age bracket 24-60 (median = 50) years.
  • None of the patients with HL and BL were HIV positive.
  • Patients with NHL presented at advanced stage of the disease (at least clinical stage IIIb), and all those with CLL presented at stage C of the International Working Party Classification.
  • All the HIV-positive patients with NHL succumbed to the disease within one to three weeks of admission into the hospital.
  • The prevalence of AIDS-related lymphomas is 2.3% compared to 4.4% found in the general population.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • All the patients presented at a very advanced stage of the disease with significantly shortened survival.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


79. Serrano D, Carrión R, Balsalobre P, Miralles P, Berenguer J, Buño I, Gómez-Pineda A, Ribera JM, Conde E, Díez-Martín JL, Spanish Cooperative Groups GELTAMO and GESIDA: HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol; 2005 Apr;33(4):487-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation.
  • OBJECTIVE: To evaluate feasibility, safety, and efficacy of peripheral blood stem cell collection (PBSCC) and autologous stem cell transplantation (ASCT), to treat patients diagnosed of high-risk or relapsed HIV-associated lymphoma (HIV+ Ly), responding to highly active antiretroviral therapy (HAART).
  • METHODS: Prospective and multicentric study in patients with high-risk or relapsed chemosensitive HIV+ Ly, candidate for consolidation with ASCT.
  • Eligibility criteria were similar to those of HIV- lymphoma.
  • Three patients died before ASCT; two had disease progression and one died from VHC-liver failure.
  • CD4+ cell counts and HIV viral load (VL) were appropriately preserved along the procedure.
  • No patients died from treatment-related complications.
  • One patient died from lymphoma progression (day +19), and another died in complete remission (CR) with undetectable VL, 15 months after transplant, due to infection.
  • CONCLUSIONS: These results show that feasibility, safety, and efficacy of PBSCC and ASCT in HIV+ Ly patients responding to HAART are similar to those observed in the HIV- lymphoma setting.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Peripheral Blood Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781340.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


80. Epeldegui M, Widney DP, Martínez-Maza O: Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol; 2006 Sep;18(5):444-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.
  • PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of AIDS-associated lymphoma.
  • RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of AIDS-associated lymphoma.
  • In addition to this, significant new information has become available on how B cell activation-associated DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in AIDS-associated lymphoma.
  • In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of AIDS-associated lymphoma.
  • SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of AIDS-associated lymphoma, and may lead to new potential targets for therapeutic intervention in these cancers.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / virology. Lymphoma, B-Cell / genetics. Oncogenic Viruses / pathogenicity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894291.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 28
  •  go-up   go-down


81. Wood C, Harrington W Jr: AIDS and associated malignancies. Cell Res; 2005 Nov-Dec;15(11-12):947-52
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and associated malignancies.
  • AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppression.
  • Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative disease.
  • In the era of potent antiretrovirals therapy (ARV), the malignant complications due to HIV-1 infection have decreased in developed nations where ARV is administered, but still poses a major problem in developing countries where HIV-1 incidence is high and ARV is still not yet widely available.
  • Even in ARV treated individuals there is a concern that the prolonged survival of many HIV-1 carriers is likely to eventually result in an increased number of malignancies diagnosed.
  • Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • The incidence of NHL has increased nearly 200 fold in HIV-positive patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of HAART therapy.
  • These AIDS related lymphomas are distinct from their counterparts seen in HIV-1 seronegative patients.
  • For example nearly half of all cases of ARL are associated with the presence of a gamma herpesvirus, Epstein Barr virus (EBV) or human herpesvirus-8 (HHV-8)/ Kaposi's sarcoma associated herpesvirus (KSHV).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. HIV / physiology. Neoplasms / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354573.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA082274; United States / NCI NIH HHS / CA / CA76958; United States / NICHD NIH HHS / HD / HD39620; United States / NCRR NIH HHS / RR / RR15635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] China
  • [Number-of-references] 60
  •  go-up   go-down


82. Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML: Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol; 2005 Jan;75(1):59-69
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
  • Epstein-Barr virus (EBV) is implicated in the pathogenesis of acquired immunodeficiency syndrome (AIDS) lymphoma, and viral DNA is present within the malignant cells in about half of affected patients.
  • We examined the extent to which EBV viral load is elevated in the plasma of AIDS lymphoma patients compared to AIDS patients with opportunistic infections.
  • Sixty-one AIDS patients were studied including 35 with lymphoma (24 non-Hodgkin, six Hodgkin, and five brain lymphoma) and 26 with various opportunistic infections.
  • In situ hybridization revealed EBV encoded RNA (EBER) expression in the malignant cells of 17/28 AIDS lymphomas (61%).
  • In 232 serial plasma samples from 35 lymphoma patients and in 128 samples from AIDS controls, EBV viral load was assayed by quantitative-polymerase chain reaction (Q-PCR) using a TaqMan probe targeting the BamH1W sequence.
  • EBV was detected in plasma from all 17 EBER-positive AIDS lymphoma patients, with viral loads ranging from 34 to 1,500,000 copies per ml (median 3,210).
  • Viral load usually fell rapidly upon initiation of lymphoma therapy and remained undetectable except in two patients with persistent tumor.
  • In 11 AIDS patients, whose lymphoma lacked EBER expression, and in 26 control patients without lymphoma, levels of EBV in plasma were usually low or undetectable (range 0-1,995 and 0-2,409, median 0 and 0, respectively).
  • There was no association between EBV viral load and human immunodeficiency virus (HIV) load or CD4 count.
  • In conclusion, EBV viral load shows promise as a tool to assist in diagnosis and management of EBV-related lymphoma patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. DNA, Viral / blood. Epstein-Barr Virus Infections / diagnosis. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Biomarkers / blood. CD4 Lymphocyte Count. Gene Expression / genetics. HIV / isolation & purification. Humans. In Situ Hybridization. Polymerase Chain Reaction. RNA, Viral / analysis. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15543571.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


83. Folk GS, Abbondanzo SL, Childers EL, Foss RD: Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol; 2006 Feb;10(1):8-12
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a clinicopathologic correlation.
  • Plasmablastic lymphoma (PBL) is an uncommon, recently described B-cell-derived lymphoma that displays distinctive affinity for extranodal presentation in the oral cavity.
  • Plasmablastic lymphoma is strongly associated with human immunodeficiency virus (HIV) infection, but has been reported in HIV-negative individuals.
  • Plasmablastic lymphoma may be poorly recognized by pathologists, which is partly attributable to its relatively rare occurrence and unusual immunophenotype.
  • Five cases of oral cavity lymphomas conforming to the current World Health Organization morphological criteria for PBL were retrieved from the consultation files at the Armed Forces Institute of Pathology.
  • Follow-up revealed only 1 patient alive with no evidence of disease.
  • Our cases show that PBL is an aggressive type of B-cell lymphoma predominantly found in the oral cavity.
  • Plasmablastic lymphoma is often associated with HIV infection.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Mouth / pathology. Mouth Neoplasms / pathology. Plasma Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16414538.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


84. Reed M, Cosgrove JM, Cindrich R, Parithivel VS, Gad Y, Bangalore M, Uzor R, Kalim J, Segura R, Albu E: Ten years later: a single hospital experience with malignancy in HIV/AIDS. J Surg Oncol; 2010 Sep 1;102(3):282-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years later: a single hospital experience with malignancy in HIV/AIDS.
  • BACKGROUND AND OBJECTIVE: We present our experience in the era of HAART with 5,112 patients having HIV infection or AIDS, treated between 2002 and 2006 in our hospital, 182 of whom had malignancies (3.56%).
  • A decrease in AIDS-defining cancers (ADC), from 63.6% to 37.3% and a higher incidence of non-AIDS-defining cancers (NADC), 62.7 as opposed to 37.9% was found.
  • No decrease in the incidence of non-Hodgkin's B cell lymphoma (NHL) was noted.
  • CONCLUSIONS: HIV/AIDS patients on HAART are older, have lower rates of AIDS related Kaposi's sarcoma and a higher incidence of NADCs than did patients in the early HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. HIV Infections / complications. Neoplasms / epidemiology


85. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH: The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood; 2010 Apr 15;115(15):3017-24
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
  • This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20(+) diffuse large B-cell lymphoma.
  • There were no treatment-related deaths or new opportunistic infections during treatment, and patients had sustained CD4 cell count recovery and HIV viral control after treatment.
  • Tumor histogenesis was the only characteristic associated with lymphoma-specific outcome with 95% of germinal center B-cell (GCB) versus 44% of non-GCB diffuse large B-cell lymphoma (DLBCL) progression-free at 5 years.
  • However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. HIV / physiology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. CD4 Lymphocyte Count. Child. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Viral Load. Young Adult


86. Gérard L, Meignin V, Galicier L, Fieschi C, Leturque N, Piketty C, Fonquernie L, Agbalika F, Oksenhendler E: Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication. AIDS; 2009 Nov 13;23(17):2301-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication.
  • OBJECTIVE: Despite effective treatment of HIV infection, some patients still develop non-Hodgkin lymphoma (NHL).
  • We analysed patients with HIV-associated NHL and undetectable plasma HIV-RNA, according to the duration of HIV suppression.
  • METHODS: Out of 388 patients included in a prospective cohort of HIV-associated NHL from 1996 to 2008, 128 (33%) had a plasma HIV-RNA below 500 copies/ml and were included in the study.
  • Patients with long-term HIV suppression (>18 months) were compared with patients with recent HIV suppression (< or = 18 months).
  • The median duration of HIV suppression was 10.1 months.
  • Most cases (65%) occurred within 18 months following HIV suppression.
  • In the more than 18 months group, patients developed NHL at a higher CD4 cell count than patients with 18 months or less of HIV suppression (359 versus 270 cells/microl, P = 0.02).
  • In addition, 52% of the tumours were Epstein-Barr virus or human herpesvirus 8 associated, without any difference in the proportion of virus-associated tumours according to the duration of HIV suppression.
  • CONCLUSION: In patients with undetectable HIV-RNA, NHL occurred mainly within the first 18 months following HIV suppression.
  • In patients developing NHL after long-term HIV suppression, the level of CD4 cell count was higher, but the association with Epstein-Barr virus or human herpesvirus 8 and the prognosis were similar to that observed in patients with recent HIV suppression.
  • [MeSH-major] HIV Infections. HIV-1. Herpesvirus 4, Human / immunology. Herpesvirus 8, Human / immunology. Lymphoma, AIDS-Related / immunology


87. Shiboski CH, Patton LL, Webster-Cyriaque JY, Greenspan D, Traboulsi RS, Ghannoum M, Jurevic R, Phelan JA, Reznik D, Greenspan JS, Oral HIV/AIDS Research Alliance, Subcommittee of the AIDS Clinical Trial Group: The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med; 2009 Jul;38(6):481-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints.
  • The Oral HIV/AIDS Research Alliance (OHARA) is part of the AIDS Clinical Trials Group (ACTG), the largest HIV clinical trials organization in the world.
  • Its main objective is to investigate oral complications associated with HIV/AIDS as the epidemic is evolving, in particular, the effects of antiretrovirals on oral mucosal lesion development and associated fungal and viral pathogens.
  • Many studies have shared end-points, which include oral diseases known to be associated with HIV/AIDS measured by trained and calibrated ACTG study nurses.
  • In preparation for future protocols, we have updated existing diagnostic criteria of the oral manifestations of HIV published in 1992 and 1993.
  • The objective of this article is to present updated case definitions for HIV-related oral diseases that will be used to measure standardized clinical end-points in OHARA studies, and that can be used by any investigator outside of OHARA/ACTG conducting clinical research that pertains to these end-points.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594839.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI068636; United States / NIAID NIH HHS / AI / U01 AI 68636
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  •  go-up   go-down


88. Yotsumoto M, Ichikawa N, Ueno M, Higuchi Y, Asano N, Kobayashi H: CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. Intern Med; 2009;48(7):559-62
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient.
  • A 49-year-old HIV-positive Japanese man was referred to our hospital for multiple skin nodules.
  • He was diagnosed with diffuse large B cell lymphoma (DLBCL) by a biopsy of the inguinal lymph node.
  • [MeSH-major] Antigens, Neoplasm / analysis. Genes, myc. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Syndecan-1 / analysis. Translocation, Genetic

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336959.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; P9G3CKZ4P5 / Ganciclovir; VAD I protocol
  •  go-up   go-down


89. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, FHDH ANRS CO4 ANRS CO141: Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr; 2009 Feb 1;50(2):206-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
  • BACKGROUND: Concerns have been raised about a possible excess risk of lymphomas in HIV-infected patients exposed to interleukin 2 (IL-2) therapy.
  • Here we compared the risks of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in IL-2-treated and IL-2-untreated HIV-infected patients.
  • METHODS: Patients monitored through the French Hospital Database on HIV between May 1, 1995, and December 31, 2005, were enrolled in this study.
  • Lymphomas that occurred between the day after study entry and the end of follow-up were eligible for analysis.
  • After adjustment for sex and time-updated age, period, the CD4 cell counts, the plasma HIV RNA levels, and AIDS status, the relative rates of NHL and HL associated with IL-2 therapy were 0.64 (95% confidence interval, 0.25 to 1.65) and 0.33 (95% confidence interval, 0.04 to 2.86), respectively.
  • CONCLUSIONS: In this large observational study, IL-2 therapy did not increase the risk of lymphoma, either NHL or HL, in HIV-infected patients.
  • [MeSH-major] HIV Infections / drug therapy. Hodgkin Disease / epidemiology. Interleukin-1 / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Databases, Factual. Female. France. Hospitals. Humans. Incidence. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131886.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong M; Lang JM; Lascaux A; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard J; Pavie J; Pialoux G; Pilorgé F; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard J; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Abgrall S; Grabar S; Guiguet M; Lanoy E; Lièvre L; Mary-Krause M; Potard V; Selinger-Leneman H; Fichou J; Bouvet E; Crickx B; Ecobichon J; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Salmon D; Sicard D; Auperin I; Gilquin J; Roudière L; Viard J; Boué F; Fior R; Delfraissy J; Goujard C; Jung C; Lesprit P; Desplanque N; Meynard JL; Meyohas M; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel J; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine J; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont J; Moreau J; Gastaut J; Retornaz F; Soubeyrand J; Allegre T; Blanc P; Galinier A; Ruiz J; Lepeu G; Granet-Brunello P; Esterni J; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang J; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand M; Yazdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M; Lévy Y; Aboulker J; Bursachi P; Delfraissy J; Saïdi Y; Lascaux A; Saïdi S; Commoy M; Chêne G; Viard JP; Molina J; Tubiana R; Lascaux AS; Berdah M; Jung C; Molina J; Lafaurie M; Schnell-Niedbalski L; Oksenhendler E; Gérard L; Delfraissy J; Goujard C; Chaix F; Rannou MT; Tegna L; Tisne-Dessus D; Jeanblanc F; Beck-Wirth G; Benomar M; Verdon R; Bazin C; Goubin P; Girard P; Boudraa C; Sebire M; Viard J; Maignan A; Tubiana R; Katlama C; Curjol A; Fabre G; Trepo C; Brochier C; Thoirain V; Bloch M; Mortier E; Dupon M; Raymond I; Ragnaud JM; Raymond I; Sellier P; Magnier JD; Simon A; Iguerstira M; Gastaut J; Dalmas AM; Aboulker J; Guéguen S; Circosta S; Mourlhou P; Saouzanet-Harel M; Izard S; Saïdi Y
  •  go-up   go-down


90. Said JW: Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol; 2007 May;14(3):189-94
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunodeficiency-related Hodgkin lymphoma and its mimics.
  • Classic Hodgkin lymphoma (CHL) in patients with underlying immunodeficiency disorders frequently differs from that in the immune competent population in terms of its clinical behavior and pathologic features.
  • Topics under review include: (a) CHL posttransplant lymphoproliferative disorders, (b) CHL in HIV/AIDS, (c) Hodgkin variant of Richter syndrome in chronic lymphocytic leukemia in association with fludarabine therapy, (d) CHL in other immunodeficiency states including methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis and primary immune deficiencies, and (e) Hodgkin-like lymphoid proliferations including senile Epstein-Barr virus+ B-cell lymphoproliferative disorder.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Hodgkin Disease / etiology. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Immunologic Deficiency Syndromes / complications. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. HIV Infections / complications. Herpesvirus 4, Human. Humans. Immunocompromised Host. Organ Transplantation / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452815.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


91. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V, Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr; 2007 Feb 1;44(2):167-73
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
  • OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).
  • METHODS: We analyzed the Grupo de Estudio del SIDA register of systemic ARL, which started in Jan 1994, to collect cases diagnosed at 15 institutions prospectively and with active follow-up every 6 months.
  • Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).
  • Factors independently associated with CR were histologic subtype and International Prognostic Index (IPI) score.
  • Factors independently associated with improved overall length of survival (OS) were CR, low IPI score, and histologic subtype.
  • The single factor independently associated with disease-free survival was Ann Arbor stage.
  • CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.
  • OS was independently associated with CR, IPI score, and the histologic subtype.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117144.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


92. Lu TH, Chang HJ, Chen LS, Chu MH, Ou NM, Jen I: Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan. J Formos Med Assoc; 2006 Jul;105(7):604-9
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan.
  • To assess the pattern of change in the causes of death among HIV/AIDS patients in Taiwan after the introduction of highly active antiretroviral therapy (HAART), national HIV/AIDS registry data were linked with cause of death and health insurance claims data from 1994 to 2002 for analysis.
  • Although HIV/AIDS remained the leading underlying cause of death among HIV/AIDS patients during the study period (552/752 = 73.4%), an increased proportion of deaths was due to non-HIV/AIDS causes (other infectious diseases, cancers, liver diseases, etc.) after the introduction of HAART in 1997.
  • Most AIDS-related conditions associated with death (cryptococcosis, cachexia/wasting, dementia/encephalopathy, etc.) decreased in frequency from 1998-2000 to 2001-2002.
  • Nonetheless, some AIDS-related conditions associated with death remained stable or increased in frequency, such as candidiasis, tuberculosis, and non-Hodgkin's lymphoma.
  • More effort is required to address the mental health of HIV/AIDS patients as a part of therapy.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877243.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  •  go-up   go-down


93. Bonnet F, Jouvencel AC, Parrens M, Leon MJ, Cotto E, Garrigue I, Morlat P, Beylot J, Fleury H, Lafon ME: A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol; 2006 Aug;36(4):258-63
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma.
  • BACKGROUND: Epstein-Barr virus (EBV) may be causally associated with non-Hodgkin Lymphoma (NHL) in HIV-infected patients.
  • OBJECTIVES: To compare EBV load in whole blood in AIDS-NHL patients, HIV non-AIDS patients and non-HIV-infected persons, and to prospectively measure EBV load in whole blood in AIDS-NHL patients.
  • RESULTS: We observed no statistical difference in EBV load between AIDS-NHL (3.69log(10) copies/mL [interquartile range (IQR): 2.89-4.27]) and HIV non-AIDS patients (3.08log(10) copies/mL [IQR: 1.29-3.57]) but AIDS-NHL patients had significantly higher EBV loads than HIV-negative controls (1.19log(10) copies/mL [IQR: 0.00-3.29]).
  • We noticed an inverse correlation between CD4+ lymphocytes count and EBV load in patients with AIDS-NHL (r(2)=0.41, P=0.01).
  • CONCLUSION: Although EBV load seems a suboptimal marker for the diagnosis of AIDS-NHL, we observed a significant decrease of EBV load in patients treated with chemotherapy and a strong association between NHL outcome and EBV load in whole blood.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / immunology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology
  • [MeSH-minor] Biomarkers, Tumor / blood. CD4 Lymphocyte Count. Cross-Sectional Studies. DNA, Viral / blood. Follow-Up Studies. HIV Seronegativity. HIV Seropositivity. Humans. Longitudinal Studies. Prospective Studies. RNA, Viral / blood. Time Factors. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762591.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


94. Yanagisawa Y, Sato Y, Asahi-Ozaki Y, Ito E, Honma R, Imai J, Kanno T, Kano M, Akiyama H, Sata T, Shinkai-Ouchi F, Yamakawa Y, Watanabe S, Katano H: Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol; 2006 Aug;209(4):464-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma.
  • Lymphoma usually forms solid tumours in patients, and high expression levels of adhesion molecules are observed in these tumours.
  • However, Kaposi's sarcoma-associated herpesvirus (KSHV)-related primary effusion lymphoma (PEL) does not form solid tumours and adhesion molecule expression is suppressed in the cells.
  • Inoculation of a KSHV-associated PEL cell line into the peritoneal cavity of severe combined immunodeficiency mice resulted in the formation of effusion and solid lymphomas in the peritoneal cavity.
  • Proteomics using two-dimensional difference gel electrophoresis and DNA microarray analyses identified 14 proteins and 105 genes, respectively, whose expression differed significantly between effusion and solid lymphomas.
  • Five genes were identified as having similar expression profiles to that of lymphocyte function-associated antigen 1, an important adhesion molecule in leukocytes.
  • Among these, coronin 1A, an actin-binding protein, was identified as a molecule showing high expression in solid lymphoma by both DNA microarray and proteomics analyses.
  • Western and northern blotting showed that coronin 1A was predominantly expressed in solid lymphomas.
  • Moreover, KSHV-encoded lytic proteins, including viral interleukin-6, were highly expressed in effusion lymphoma compared with solid lymphoma.
  • These data demonstrate that effusion and solid lymphomas possess distinctive gene and protein expression profiles in our mouse model, and suggest that differences in gene and protein expression between effusion and solid lymphomas may be associated with the formation of effusion lymphoma or invasive features of solid lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, AIDS-Related / genetics. Sarcoma, Kaposi / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA, Viral / analysis. Electrophoresis, Gel, Two-Dimensional. Gene Expression Profiling. Humans. Lymphocyte Function-Associated Antigen-1 / genetics. Mice. Mice, SCID. Models, Animal. Oligonucleotide Array Sequence Analysis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / virology. Proteomics. Reverse Transcriptase Polymerase Chain Reaction. Viral Proteins / analysis

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16741895.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Lymphocyte Function-Associated Antigen-1; 0 / Viral Proteins
  •  go-up   go-down


95. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancy and human immunodeficiency virus disease.
  • Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.
  • [MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


96. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol; 2005 Jul 1;23(19):4372-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
  • PURPOSE: Primary effusion lymphoma (PEL) is a rare high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
  • To date, no prognostic factor has been identified in this subset of lymphoma.
  • PATIENTS AND METHODS: We describe here a large series of HIV-infected patients with PEL, including 28 cases diagnosed in six centers during an 11-year time period.
  • Fourteen patients (50%) achieved complete remission, with a 1-year disease-free survival rate at 78.6%.
  • CONCLUSION: Based on a retrospective series of 28 patients, two prognostic factors were identified as being independently associated with impaired clinical outcome in HIV-related PEL--(1) a poor performance status and (2) the absence of HAART before PEL diagnosis.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Herpesvirus 8, Human. Lymphoma, AIDS-Related / mortality


97. Dales JP, Harket A, Bagnères D, Andrac-Meyer L, Xerri L, Frances Y, Taranger-Charpin C: [Plasmablastic lymphoma in a patient with HIV infection: an unusual case located in the skin]. Ann Pathol; 2005 Feb;25(1):45-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasmablastic lymphoma in a patient with HIV infection: an unusual case located in the skin].
  • [Transliterated title] Lymphome plasmoblastique du sujet infecté par le VIH: a propos d'un cas très inhabituel de localisation cutanée.
  • We report the case of a plasmablastic lymphoma involving the skin in a 45 year-old HIV-positive patient.
  • Plasmablastic lymphoma was first described in 1997 and is considered to be a diffuse large B-cell lymphoma with a unique immunophenotype and a predilection for the oral cavity.
  • A skin biopsy led to the diagnosis of plasmablastic lymphoma in view of the presence of a dense nodular infiltrate invading the dermis and subcutaneous fat composed of large cells that expressed neither the leucocyte common antigen nor the B- and T-cell antigens CD20 and CD3, but which showed a strong immunostaining with plasma cell marker VS38c.
  • HIV-associated plasmablastic lymphoma is a poor prognosis malignancy that may resist typing due to the lack of expression of commonly used lymphoid markers.
  • [MeSH-major] HIV Seropositivity / complications. Lymphoma, AIDS-Related / diagnosis. Plasma Cells. Skin Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Humans. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981931.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


98. Richard V, Nadella MV, Green PL, Lairmore MD, Feuer G, Foley JG, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia; 2005 Jul;19(7):1175-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy seen in the majority of adult T-cell leukemia/lymphoma (ATLL) patients with human T-cell lymphotropic virus type-1 (HTLV-1) infection.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1583-90 [11080795.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46661-70 [11590145.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):799-805 [12632071.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jun 30;204(1-2):155-68 [12850290.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Oct;81(19):6207-11 [6091140.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] J Immunol. 1989 Aug 15;143(4):1283-9 [2545785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Mar 30;167(3):1134-8 [2322262.001]
  • [Cites] J Virol. 1990 Jun;64(6):2825-32 [2335818.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13623-8 [1618864.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1017-24 [8427983.001]
  • [Cites] Cancer. 1993 May 1;71(9):2803-6 [8467460.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2551-6 [8099324.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2980-6 [8319205.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16730-6 [8393873.001]
  • [Cites] J Virol. 1993 Oct;67(10):6087-95 [8371355.001]
  • [Cites] Urology. 1994 May;43(5):675-9 [8165768.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):639-44 [8053392.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8960-3 [8090753.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1782-9 [7895691.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4064-75 [7623802.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2257-67 [7662973.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):702-7 [7669584.001]
  • [Cites] Mol Cell Endocrinol. 1995 Jun;111(2):225-32 [7556886.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Cell Physiol. 1996 Jan;166(1):1-11 [8557757.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11463-71 [9565558.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14119-29 [9603911.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):6015-22 [10606251.001]
  • [Cites] Mol Cell Endocrinol. 1999 Oct 25;156(1-2):13-23 [10612419.001]
  • (PMID = 15889157.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; United States / NCI NIH HHS / CA / P01 CA100730-03; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-03; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Ets1 protein, mouse; 0 / Gene Products, rex; 0 / Gene Products, tax; 0 / Parathyroid Hormone-Related Protein; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell; 0 / Transcription Factors; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS94146; NLM/ PMC2661941
  •  go-up   go-down


99. Girard T, Luquet-Besson I, Baran-Marszak F, Raphaël M, Boué F: HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone. Eur J Haematol; 2005 Jan;74(1):70-2
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone.
  • MALT lymphoma is usually described in association with Helicobacter pylori, HCV, HHV8, Campylobacter jejuni or in a setting of overreactive immunity.
  • In HIV(+) patients, MALT lymphoma is most commonly described in children.
  • We describe here an original case of HIV(+) MALT lymphoma with bronchial, conjuctival and laryngeal involvement for which a clinical and histopathological remission has been obtained with HAART alone.
  • We conclude that HIV, as well as H. pylori, C. jejuni and HCV can target lymphogenesis in MALT lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, B-Cell, Marginal Zone / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613110.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


100. Okada S: [Recent advances in the treatment of AIDS-related malignant lymphoma]. Nihon Rinsho; 2010 Mar;68(3):491-6
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent advances in the treatment of AIDS-related malignant lymphoma].
  • The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • However, the number of HIV-associated non-Hodgkin's lymphoma patients has increased with the increase of HIV-1 infected patients in Japan.
  • Although the evidence currently supports an intensive and curative approach for the management of HIV-associated lymphoma, we must be vigilant about adverse effects and interaction of chemotherapeutic drugs, implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229796.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 29
  •  go-up   go-down






Advertisement